WO2014011906A2

WO2014011906A2 - Inhibiteurs d'irak et leurs utilisations

Inhibiteurs d'irak et leurs utilisations Download PDF

Info

Publication number: WO2014011906A2
Authority: WO; WIPO (PCT)
Prior art keywords: disease; compound; ring; irak; compounds
Prior art date: 2012-07-11

Application number

PCT/US2013/050113

Other languages

English (en)

Other versions

WO2014011906A3 (fr

Inventor

Geraldine C. Harriman

Ronald T. Wester

Donna L. Romero

Craig E. Masse

Shaughnessy Robinson

Jeremy Robert Greenwood

Original Assignee

Nimbus Iris, Inc.

Priority date

2012-07-11

Filing date

2013-07-11

Publication date

2014-01-16

Priority claimed from US201261670380P external-priority

2013-07-11 Application filed by Nimbus Iris, Inc. filed Critical Nimbus Iris, Inc.

2013-07-11 Priority to CN201380036906.2A priority Critical patent/CN104902959A/zh

2013-07-11 Priority to EP13817012.1A priority patent/EP2872518A4/fr

2013-07-11 Priority to CA2878040A priority patent/CA2878040A1/fr

2013-07-11 Priority to IN127DEN2015 priority patent/IN2015DN00127A/en

2013-07-11 Priority to AU2013290080A priority patent/AU2013290080A1/en

2013-07-11 Priority to JP2015521817A priority patent/JP2015528801A/ja

2013-07-11 Priority to BR112015000561A priority patent/BR112015000561A2/pt

2014-01-16 Publication of WO2014011906A2 publication Critical patent/WO2014011906A2/fr

2015-07-16 Publication of WO2014011906A3 publication Critical patent/WO2014011906A3/fr

2015-11-19 Priority to HK15111414.8A priority patent/HK1210732A1/xx

Links

230000002401 inhibitory effect Effects 0.000 title claims description 148
239000003112 inhibitor Substances 0.000 title description 104
150000001875 compounds Chemical class 0.000 claims abstract description 358
IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 118
201000010099 disease Diseases 0.000 claims description 117
229910052757 nitrogen Inorganic materials 0.000 claims description 87
-1 thiono Chemical group 0.000 claims description 76
239000011780 sodium chloride Substances 0.000 claims description 64
125000005842 heteroatoms Chemical group 0.000 claims description 63
229910052717 sulfur Chemical group 0.000 claims description 63
NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 62
239000011593 sulfur Chemical group 0.000 claims description 62
229910052760 oxygen Inorganic materials 0.000 claims description 60
239000001301 oxygen Chemical group 0.000 claims description 60
MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical group O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 60
150000003839 salts Chemical class 0.000 claims description 57
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 54
101700044314 IRAK4 Proteins 0.000 claims description 51
102100016185 IRAK4 Human genes 0.000 claims description 51
125000000623 heterocyclic group Chemical group 0.000 claims description 42
208000006673 Asthma Diseases 0.000 claims description 41
125000001931 aliphatic group Chemical group 0.000 claims description 32
101700063385 IRAK1 Proteins 0.000 claims description 28
102100016182 IRAK1 Human genes 0.000 claims description 28
230000001684 chronic Effects 0.000 claims description 26
125000004429 atoms Chemical group 0.000 claims description 25
229910052736 halogen Inorganic materials 0.000 claims description 24
201000011510 cancer Diseases 0.000 claims description 23
150000002367 halogens Chemical class 0.000 claims description 23
200000000018 inflammatory disease Diseases 0.000 claims description 23
125000002619 bicyclic group Chemical group 0.000 claims description 22
206010028980 Neoplasm Diseases 0.000 claims description 21
201000008937 atopic dermatitis Diseases 0.000 claims description 19
125000004093 cyano group Chemical group *C#N 0.000 claims description 19
108010002352 Interleukin-1 Proteins 0.000 claims description 18
229910052739 hydrogen Inorganic materials 0.000 claims description 18
239000001257 hydrogen Substances 0.000 claims description 18
230000001404 mediated Effects 0.000 claims description 18
206010012818 Diffuse large B-cell lymphoma Diseases 0.000 claims description 17
230000001363 autoimmune Effects 0.000 claims description 17
125000002837 carbocyclic group Chemical group 0.000 claims description 17
125000001072 heteroaryl group Chemical group 0.000 claims description 17
206010020751 Hypersensitivity Diseases 0.000 claims description 16
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 16
210000004027 cells Anatomy 0.000 claims description 15
206010035226 Plasma cell myeloma Diseases 0.000 claims description 14
201000005569 gout Diseases 0.000 claims description 14
201000009251 multiple myeloma Diseases 0.000 claims description 13
239000012472 biological sample Substances 0.000 claims description 12
210000000056 organs Anatomy 0.000 claims description 12
230000002062 proliferating Effects 0.000 claims description 12
VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 12
238000002054 transplantation Methods 0.000 claims description 12
206010039073 Rheumatoid arthritis Diseases 0.000 claims description 11
210000003491 Skin Anatomy 0.000 claims description 11
230000000172 allergic Effects 0.000 claims description 11
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 11
201000004681 psoriasis Diseases 0.000 claims description 11
206010061218 Inflammation Diseases 0.000 claims description 10
208000000429 Leukemia, Lymphocytic, Chronic, B-Cell Diseases 0.000 claims description 10
230000004054 inflammatory process Effects 0.000 claims description 10
201000006417 multiple sclerosis Diseases 0.000 claims description 10
239000003981 vehicle Substances 0.000 claims description 10
125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 9
206010006451 Bronchitis Diseases 0.000 claims description 9
206010021972 Inflammatory bowel disease Diseases 0.000 claims description 9
206010053643 Neurodegenerative disease Diseases 0.000 claims description 9
206010039710 Scleroderma Diseases 0.000 claims description 9
230000001154 acute Effects 0.000 claims description 9
201000005794 allergic hypersensitivity disease Diseases 0.000 claims description 9
238000006243 chemical reaction Methods 0.000 claims description 9
201000009910 diseases by infectious agent Diseases 0.000 claims description 9
239000003937 drug carrier Substances 0.000 claims description 9
201000000596 systemic lupus erythematosus Diseases 0.000 claims description 9
208000008787 Cardiovascular Disease Diseases 0.000 claims description 8
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 8
206010009900 Colitis ulcerative Diseases 0.000 claims description 8
206010012438 Dermatitis atopic Diseases 0.000 claims description 8
229940088597 Hormone Drugs 0.000 claims description 8
206010037162 Psoriatic arthropathy Diseases 0.000 claims description 8
239000002671 adjuvant Substances 0.000 claims description 8
230000000240 adjuvant Effects 0.000 claims description 8
239000005556 hormone Substances 0.000 claims description 8
201000008482 osteoarthritis Diseases 0.000 claims description 8
201000001263 psoriatic arthritis Diseases 0.000 claims description 8
201000006704 ulcerative colitis Diseases 0.000 claims description 8
206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 7
206010003816 Autoimmune disease Diseases 0.000 claims description 7
206010008958 Chronic lymphocytic leukaemia Diseases 0.000 claims description 7
206010010741 Conjunctivitis Diseases 0.000 claims description 7
206010011401 Crohn's disease Diseases 0.000 claims description 7
206010013774 Dry eye Diseases 0.000 claims description 7
208000002250 Hematologic Neoplasms Diseases 0.000 claims description 7
206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims description 7
206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 7
208000009319 Keratoconjunctivitis Sicca Diseases 0.000 claims description 7
206010028417 Myasthenia gravis Diseases 0.000 claims description 7
206010039085 Rhinitis allergic Diseases 0.000 claims description 7
206010047115 Vasculitis Diseases 0.000 claims description 7
208000001756 Virus Disease Diseases 0.000 claims description 7
201000010105 allergic rhinitis Diseases 0.000 claims description 7
201000001981 dermatomyositis Diseases 0.000 claims description 7
201000011152 pemphigus Diseases 0.000 claims description 7
239000008194 pharmaceutical composition Substances 0.000 claims description 7
206010069351 Acute lung injury Diseases 0.000 claims description 6
206010001897 Alzheimer's disease Diseases 0.000 claims description 6
208000009899 Burkitt Lymphoma Diseases 0.000 claims description 6
206010009839 Coeliac disease Diseases 0.000 claims description 6
206010010744 Conjunctivitis allergic Diseases 0.000 claims description 6
208000001591 Cryopyrin-Associated Periodic Syndrome Diseases 0.000 claims description 6
206010020243 Hodgkin's disease Diseases 0.000 claims description 6
208000006897 Interstitial Lung Disease Diseases 0.000 claims description 6
208000003456 Juvenile Arthritis Diseases 0.000 claims description 6
210000004072 Lung Anatomy 0.000 claims description 6
208000008466 Metabolic Disease Diseases 0.000 claims description 6
206010029164 Nephrotic syndrome Diseases 0.000 claims description 6
108009000551 Nephrotic syndrome Proteins 0.000 claims description 6
206010033645 Pancreatitis Diseases 0.000 claims description 6
210000002307 Prostate Anatomy 0.000 claims description 6
206010040767 Sjogren's syndrome Diseases 0.000 claims description 6
206010052779 Transplant rejections Diseases 0.000 claims description 6
206010046851 Uveitis Diseases 0.000 claims description 6
239000002253 acid Substances 0.000 claims description 6
201000009030 carcinoma Diseases 0.000 claims description 6
201000001155 extrinsic allergic alveolitis Diseases 0.000 claims description 6
230000002496 gastric Effects 0.000 claims description 6
201000007919 lymphoplasmacytic lymphoma Diseases 0.000 claims description 6
201000002481 myositis Diseases 0.000 claims description 6
201000008383 nephritis Diseases 0.000 claims description 6
201000009890 sinusitis Diseases 0.000 claims description 6
208000009137 Behcet Syndrome Diseases 0.000 claims description 5
201000008335 Behcet's disease Diseases 0.000 claims description 5
208000003432 Bone Disease Diseases 0.000 claims description 5
210000000988 Bone and Bones Anatomy 0.000 claims description 5
208000000594 Bullous Pemphigoid Diseases 0.000 claims description 5
206010012601 Diabetes mellitus Diseases 0.000 claims description 5
206010018634 Gouty arthritis Diseases 0.000 claims description 5
206010018651 Graft versus host disease Diseases 0.000 claims description 5
208000009329 Graft vs Host Disease Diseases 0.000 claims description 5
201000004779 Graves' disease Diseases 0.000 claims description 5
208000001083 Kidney Disease Diseases 0.000 claims description 5
208000001145 Metabolic Syndrome Diseases 0.000 claims description 5
206010029151 Nephropathy Diseases 0.000 claims description 5
208000008589 Obesity Diseases 0.000 claims description 5
206010061536 Parkinson's disease Diseases 0.000 claims description 5
206010034277 Pemphigoid Diseases 0.000 claims description 5
210000000664 Rectum Anatomy 0.000 claims description 5
206010047642 Vitiligo Diseases 0.000 claims description 5
201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 5
201000004624 dermatitis Diseases 0.000 claims description 5
231100000406 dermatitis Toxicity 0.000 claims description 5
125000005843 halogen group Chemical group 0.000 claims description 5
201000009673 liver disease Diseases 0.000 claims description 5
235000020824 obesity Nutrition 0.000 claims description 5
201000010874 syndrome Diseases 0.000 claims description 5
206010056508 Acquired epidermolysis bullosa Diseases 0.000 claims description 4
201000004304 Addison's disease Diseases 0.000 claims description 4
208000004631 Alopecia Areata Diseases 0.000 claims description 4
206010002198 Anaphylactic reaction Diseases 0.000 claims description 4
208000003455 Anaphylaxis Diseases 0.000 claims description 4
206010002967 Aplastic anaemia Diseases 0.000 claims description 4
206010003011 Appendicitis Diseases 0.000 claims description 4
206010004661 Biliary cirrhosis primary Diseases 0.000 claims description 4
206010012468 Dermatitis herpetiformis Diseases 0.000 claims description 4
206010014599 Encephalitis Diseases 0.000 claims description 4
208000004232 Enteritis Diseases 0.000 claims description 4
206010014950 Eosinophilia Diseases 0.000 claims description 4
206010015150 Erythema Diseases 0.000 claims description 4
208000007882 Gastritis Diseases 0.000 claims description 4
206010018364 Glomerulonephritis Diseases 0.000 claims description 4
208000006454 Hepatitis Diseases 0.000 claims description 4
201000006743 Hodgkin's lymphoma Diseases 0.000 claims description 4
206010052739 Immunodeficiency disorder Diseases 0.000 claims description 4
206010022114 Injury Diseases 0.000 claims description 4
206010024324 Leukaemias Diseases 0.000 claims description 4
206010024377 Leukocytoclastic vasculitis Diseases 0.000 claims description 4
208000009856 Lung Disease Diseases 0.000 claims description 4
206010025323 Lymphomas Diseases 0.000 claims description 4
208000009525 Myocarditis Diseases 0.000 claims description 4
210000001331 Nose Anatomy 0.000 claims description 4
206010031149 Osteitis Diseases 0.000 claims description 4
206010035664 Pneumonia Diseases 0.000 claims description 4
206010035742 Pneumonitis Diseases 0.000 claims description 4
206010042953 Systemic sclerosis Diseases 0.000 claims description 4
206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 4
206010046736 Urticarias Diseases 0.000 claims description 4
208000004762 Vasculitis, Leukocytoclastic, Cutaneous Diseases 0.000 claims description 4
230000036783 anaphylactic response Effects 0.000 claims description 4
230000001066 destructive Effects 0.000 claims description 4
201000011114 epidermolysis bullosa acquisita Diseases 0.000 claims description 4
231100000321 erythema Toxicity 0.000 claims description 4
231100000283 hepatitis Toxicity 0.000 claims description 4
125000004435 hydrogen atoms Chemical group [H]* 0.000 claims description 4
125000001841 imino group Chemical group [H]N=* 0.000 claims description 4
201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims description 4
201000009906 meningitis Diseases 0.000 claims description 4
125000004043 oxo group Chemical group O=* 0.000 claims description 4
230000001575 pathological Effects 0.000 claims description 4
201000001976 pemphigus vulgaris Diseases 0.000 claims description 4
201000002728 primary biliary cirrhosis Diseases 0.000 claims description 4
201000004595 synovitis Diseases 0.000 claims description 4
201000009594 systemic scleroderma Diseases 0.000 claims description 4
201000005539 vernal conjunctivitis Diseases 0.000 claims description 4
208000009956 Adenocarcinoma Diseases 0.000 claims description 3
208000003200 Adenoma Diseases 0.000 claims description 3
206010001233 Adenoma benign Diseases 0.000 claims description 3
210000004100 Adrenal Glands Anatomy 0.000 claims description 3
206010001889 Alveolitis Diseases 0.000 claims description 3
206010002026 Amyotrophic lateral sclerosis Diseases 0.000 claims description 3
208000007502 Anemia Diseases 0.000 claims description 3
206010073480 B-cell prolymphocytic leukaemia Diseases 0.000 claims description 3
208000010217 Blepharitis Diseases 0.000 claims description 3
210000004556 Brain Anatomy 0.000 claims description 3
210000000481 Breast Anatomy 0.000 claims description 3
206010066091 Bronchial hyperreactivity Diseases 0.000 claims description 3
206010006448 Bronchiolitis Diseases 0.000 claims description 3
206010067184 Burkitt's leukaemia Diseases 0.000 claims description 3
206010006811 Bursitis Diseases 0.000 claims description 3
206010008120 Cerebral ischaemia Diseases 0.000 claims description 3
206010008323 Cervicitis Diseases 0.000 claims description 3
210000003679 Cervix Uteri Anatomy 0.000 claims description 3
208000003167 Cholangitis Diseases 0.000 claims description 3
206010009887 Colitis Diseases 0.000 claims description 3
210000001072 Colon Anatomy 0.000 claims description 3
206010009944 Colon cancer Diseases 0.000 claims description 3
206010011841 Dacryoadenitis acquired Diseases 0.000 claims description 3
206010061818 Disease progression Diseases 0.000 claims description 3
206010014013 Ear infection Diseases 0.000 claims description 3
206010014665 Endocarditis Diseases 0.000 claims description 3
208000004145 Endometritis Diseases 0.000 claims description 3
208000010227 Enterocolitis Diseases 0.000 claims description 3
210000003238 Esophagus Anatomy 0.000 claims description 3
206010016228 Fasciitis Diseases 0.000 claims description 3
208000001640 Fibromyalgia Diseases 0.000 claims description 3
208000005577 Gastroenteritis Diseases 0.000 claims description 3
208000005017 Glioblastoma Diseases 0.000 claims description 3
210000003128 Head Anatomy 0.000 claims description 3
208000007475 Hemolytic Anemia Diseases 0.000 claims description 3
201000004331 Henoch-Schoenlein purpura Diseases 0.000 claims description 3
206010019617 Henoch-Schonlein purpura Diseases 0.000 claims description 3
206010019755 Hepatitis chronic active Diseases 0.000 claims description 3
208000002557 Hidradenitis Diseases 0.000 claims description 3
201000001971 Huntington's disease Diseases 0.000 claims description 3
206010048643 Hypereosinophilic syndrome Diseases 0.000 claims description 3
206010020718 Hyperplasia Diseases 0.000 claims description 3
206010021143 Hypoxia Diseases 0.000 claims description 3
208000010159 IGA Glomerulonephritis Diseases 0.000 claims description 3
208000005615 Interstitial Cystitis Diseases 0.000 claims description 3
208000002551 Irritable Bowel Syndrome Diseases 0.000 claims description 3
206010023332 Keratitis Diseases 0.000 claims description 3
206010023347 Keratoacanthoma Diseases 0.000 claims description 3
210000003734 Kidney Anatomy 0.000 claims description 3
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 3
208000003849 Large Cell Carcinoma Diseases 0.000 claims description 3
210000000867 Larynx Anatomy 0.000 claims description 3
208000001152 Leukemia, Prolymphocytic, B-Cell Diseases 0.000 claims description 3
210000004185 Liver Anatomy 0.000 claims description 3
206010052178 Lymphocytic lymphoma Diseases 0.000 claims description 3
206010025650 Malignant melanoma Diseases 0.000 claims description 3
208000004396 Mastitis Diseases 0.000 claims description 3
208000003926 Myelitis Diseases 0.000 claims description 3
206010029149 Nephropathy Diseases 0.000 claims description 3
206010029260 Neuroblastoma Diseases 0.000 claims description 3
206010029350 Neurotoxicity Diseases 0.000 claims description 3
208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 claims description 3
208000005963 Oophoritis Diseases 0.000 claims description 3
208000005141 Otitis Diseases 0.000 claims description 3
210000001672 Ovary Anatomy 0.000 claims description 3
210000000496 Pancreas Anatomy 0.000 claims description 3
206010057056 Paraneoplastic pemphigus Diseases 0.000 claims description 3
206010034038 Parotitis Diseases 0.000 claims description 3
208000008494 Pericarditis Diseases 0.000 claims description 3
206010034674 Peritonitis Diseases 0.000 claims description 3
208000001297 Phlebitis Diseases 0.000 claims description 3
208000007452 Plasmacytoma Diseases 0.000 claims description 3
208000008423 Pleurisy Diseases 0.000 claims description 3
206010065159 Polychondritis Diseases 0.000 claims description 3
208000005987 Polymyositis Diseases 0.000 claims description 3
208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 3
206010065857 Primary effusion lymphoma Diseases 0.000 claims description 3
206010036774 Proctitis Diseases 0.000 claims description 3
206010037596 Pyelonephritis Diseases 0.000 claims description 3
206010039083 Rhinitis Diseases 0.000 claims description 3
208000007893 Salpingitis Diseases 0.000 claims description 3
206010039491 Sarcoma Diseases 0.000 claims description 3
208000005511 Schoenlein-Henoch Purpura Diseases 0.000 claims description 3
206010062113 Splenic marginal zone lymphoma Diseases 0.000 claims description 3
208000010110 Spontaneous Platelet Aggregation Diseases 0.000 claims description 3
206010041823 Squamous cell carcinoma Diseases 0.000 claims description 3
210000002784 Stomach Anatomy 0.000 claims description 3
208000003265 Stomatitis Diseases 0.000 claims description 3
206010043255 Tendonitis Diseases 0.000 claims description 3
210000001550 Testis Anatomy 0.000 claims description 3
210000001685 Thyroid Gland Anatomy 0.000 claims description 3
206010043778 Thyroiditis Diseases 0.000 claims description 3
206010044008 Tonsillitis Diseases 0.000 claims description 3
206010044221 Toxic encephalopathy Diseases 0.000 claims description 3
208000001072 Type 2 Diabetes Mellitus Diseases 0.000 claims description 3
210000003932 Urinary Bladder Anatomy 0.000 claims description 3
208000006374 Uterine Cervicitis Diseases 0.000 claims description 3
210000001215 Vagina Anatomy 0.000 claims description 3
206010046914 Vaginal infection Diseases 0.000 claims description 3
208000002003 Vulvitis Diseases 0.000 claims description 3
201000005510 acute lymphocytic leukemia Diseases 0.000 claims description 3
230000032683 aging Effects 0.000 claims description 3
201000009596 autoimmune hypersensitivity disease Diseases 0.000 claims description 3
201000008975 bone inflammation disease Diseases 0.000 claims description 3
201000006474 brain ischemia Diseases 0.000 claims description 3
201000008275 breast carcinoma Diseases 0.000 claims description 3
230000036427 bronchial hyperreactivity Effects 0.000 claims description 3
230000020411 cell activation Effects 0.000 claims description 3
230000030833 cell death Effects 0.000 claims description 3
201000001352 cholecystitis Diseases 0.000 claims description 3
201000003963 colon carcinoma Diseases 0.000 claims description 3
201000002758 colorectal adenoma Diseases 0.000 claims description 3
201000003146 cystitis Diseases 0.000 claims description 3
201000004400 dacryoadenitis Diseases 0.000 claims description 3
230000002124 endocrine Effects 0.000 claims description 3
201000009273 endometriosis Diseases 0.000 claims description 3
201000011275 epicondylitis Diseases 0.000 claims description 3
201000010063 epididymitis Diseases 0.000 claims description 3
201000005160 follicular thyroid carcinoma Diseases 0.000 claims description 3
230000002489 hematologic Effects 0.000 claims description 3
201000007162 hidradenitis suppurativa Diseases 0.000 claims description 3
230000001146 hypoxic Effects 0.000 claims description 3
201000010666 keratoconjunctivitis Diseases 0.000 claims description 3
201000008197 laryngitis Diseases 0.000 claims description 3
201000005244 lung non-small cell carcinoma Diseases 0.000 claims description 3
201000001441 melanoma Diseases 0.000 claims description 3
201000005962 mycosis fungoide Diseases 0.000 claims description 3
230000002887 neurotoxic Effects 0.000 claims description 3
231100000228 neurotoxicity Toxicity 0.000 claims description 3
201000005737 orchitis Diseases 0.000 claims description 3
201000010198 papillary carcinoma Diseases 0.000 claims description 3
201000007100 pharyngitis Diseases 0.000 claims description 3
201000007094 prostatitis Diseases 0.000 claims description 3
238000007634 remodeling Methods 0.000 claims description 3
201000000306 sarcoidosis Diseases 0.000 claims description 3
201000010208 seminoma Diseases 0.000 claims description 3
201000008100 vaginitis Diseases 0.000 claims description 3
206010001627 Alcoholic liver disease Diseases 0.000 claims description 2
201000004940 Bloch-Sulzberger syndrome Diseases 0.000 claims description 2
206010007558 Cardiac failure chronic Diseases 0.000 claims description 2
206010007572 Cardiac hypertrophy Diseases 0.000 claims description 2
208000002177 Cataract Diseases 0.000 claims description 2
208000007784 Diverticulitis Diseases 0.000 claims description 2
206010058314 Dysplasia Diseases 0.000 claims description 2
206010015037 Epilepsy Diseases 0.000 claims description 2
208000001362 Fetal Growth Retardation Diseases 0.000 claims description 2
206010070531 Foetal growth restriction Diseases 0.000 claims description 2
208000010412 Glaucoma Diseases 0.000 claims description 2
206010019233 Headache Diseases 0.000 claims description 2
208000008674 Hereditary Autoinflammatory Disease Diseases 0.000 claims description 2
206010061205 Hereditary disease Diseases 0.000 claims description 2
208000000203 Hyaline Membrane Disease Diseases 0.000 claims description 2
208000007031 Incontinentia Pigmenti Diseases 0.000 claims description 2
208000004852 Lung Injury Diseases 0.000 claims description 2
208000003543 Lymphoma, T-Cell, Cutaneous Diseases 0.000 claims description 2
208000003393 Mammary Paget's Disease Diseases 0.000 claims description 2
206010027406 Mesothelioma Diseases 0.000 claims description 2
206010028289 Muscle atrophy Diseases 0.000 claims description 2
108010082739 NADPH Oxidase 2 Proteins 0.000 claims description 2
206010028974 Neonatal respiratory distress syndrome Diseases 0.000 claims description 2
208000010191 Osteitis Deformans Diseases 0.000 claims description 2
208000002193 Pain Diseases 0.000 claims description 2
206010036105 Polyneuropathy Diseases 0.000 claims description 2
208000004358 Polyneuropathy Diseases 0.000 claims description 2
208000002815 Pulmonary Hypertension Diseases 0.000 claims description 2
206010038428 Renal disease Diseases 0.000 claims description 2
206010042970 T-cell chronic lymphocytic leukaemia Diseases 0.000 claims description 2
206010069363 Traumatic lung injury Diseases 0.000 claims description 2
230000001925 catabolic Effects 0.000 claims description 2
201000009446 chronic granulomatous disease Diseases 0.000 claims description 2
201000009541 complex regional pain syndrome Diseases 0.000 claims description 2
201000007241 cutaneous T cell lymphoma Diseases 0.000 claims description 2
201000003883 cystic fibrosis Diseases 0.000 claims description 2
231100000852 glomerular disease Toxicity 0.000 claims description 2
231100000869 headache Toxicity 0.000 claims description 2
201000010238 heart disease Diseases 0.000 claims description 2
230000009610 hypersensitivity Effects 0.000 claims description 2
201000008319 inclusion body myositis Diseases 0.000 claims description 2
201000011486 lichen planus Diseases 0.000 claims description 2
231100000515 lung injury Toxicity 0.000 claims description 2
201000000585 muscular atrophy Diseases 0.000 claims description 2
201000002652 newborn respiratory distress syndrome Diseases 0.000 claims description 2
201000001245 periodontitis Diseases 0.000 claims description 2
201000011056 retinal disease Diseases 0.000 claims description 2
239000000377 silicon dioxide Substances 0.000 claims description 2
102000010168 Myeloid Differentiation Factor 88 Human genes 0.000 claims 2
108010077432 Myeloid Differentiation Factor 88 Proteins 0.000 claims 2
125000001183 hydrocarbyl group Chemical group 0.000 claims 2
NKCXQMYPWXSLIZ-PSRDDEIFSA-N (2S)-2-[[(2S)-1-[(2S)-5-amino-2-[[2-[[(2S)-6-amino-2-[[2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-amino-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-hydroxybutanoyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]-3-m Chemical compound O=C([C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](N)[C@@H](C)O)[C@@H](C)O)C(C)C)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O NKCXQMYPWXSLIZ-PSRDDEIFSA-N 0.000 claims 1
102000004180 NADPH Oxidase 2 Human genes 0.000 claims 1
108090000190 Thrombin Proteins 0.000 claims 1
229960004072 thrombin Drugs 0.000 claims 1
239000000203 mixture Substances 0.000 abstract description 165
239000002175 thienopyridine Substances 0.000 abstract 1
230000000694 effects Effects 0.000 description 76
239000003814 drug Substances 0.000 description 68
235000002639 sodium chloride Nutrition 0.000 description 56
239000000243 solution Substances 0.000 description 52
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 47
239000003795 chemical substances by application Substances 0.000 description 35
102000001253 Protein Kinases Human genes 0.000 description 30
XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 29
125000001424 substituent group Chemical group 0.000 description 26
102000002689 toll-like receptors Human genes 0.000 description 26
108020000411 toll-like receptors Proteins 0.000 description 26
230000015572 biosynthetic process Effects 0.000 description 25
ZFXYFBGIUFBOJW-UHFFFAOYSA-N Theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 24
238000003786 synthesis reaction Methods 0.000 description 23
230000002194 synthesizing Effects 0.000 description 23
230000003247 decreasing Effects 0.000 description 22
102000006940 Interleukin-1 Receptor-Associated Kinases Human genes 0.000 description 21
108010072621 Interleukin-1 Receptor-Associated Kinases Proteins 0.000 description 21
YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 21
230000011664 signaling Effects 0.000 description 21
239000007787 solid Substances 0.000 description 21
101700047088 IRAK2 Proteins 0.000 description 20
102100016181 IRAK2 Human genes 0.000 description 20
108091000081 Phosphotransferases Proteins 0.000 description 19
125000003118 aryl group Chemical group 0.000 description 19
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 18
102000004965 antibodies Human genes 0.000 description 17
108090001123 antibodies Proteins 0.000 description 17
239000002552 dosage form Substances 0.000 description 17
229940079593 drugs Drugs 0.000 description 17
102000000589 Interleukin-1 Human genes 0.000 description 16
239000003921 oil Substances 0.000 description 15
235000019198 oils Nutrition 0.000 description 15
102000004169 proteins and genes Human genes 0.000 description 15
108090000623 proteins and genes Proteins 0.000 description 15
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 14
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 14
150000002430 hydrocarbons Chemical group 0.000 description 14
238000002560 therapeutic procedure Methods 0.000 description 14
150000002431 hydrogen Chemical group 0.000 description 13
230000002757 inflammatory Effects 0.000 description 13
238000004949 mass spectrometry Methods 0.000 description 13
KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone dipropionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 description 12
229940064701 Corticosteroid nasal preparations for topical use Drugs 0.000 description 12
229960001334 Corticosteroids Drugs 0.000 description 12
102100010074 MYD88 Human genes 0.000 description 12
101700079836 MYD88 Proteins 0.000 description 12
102000003993 Phosphatidylinositol 3-Kinases Human genes 0.000 description 12
108090000430 Phosphatidylinositol 3-Kinases Proteins 0.000 description 12
NDAUXUAQIAJITI-UHFFFAOYSA-N Salbutamol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 12
230000027455 binding Effects 0.000 description 12
125000004432 carbon atoms Chemical group C* 0.000 description 12
239000003246 corticosteroid Substances 0.000 description 12
239000000126 substance Substances 0.000 description 12
230000001225 therapeutic Effects 0.000 description 12
229940083878 topical for treatment of hemorrhoids and anal fissures Corticosteroids Drugs 0.000 description 12
108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 description 11
102100009312 BTK Human genes 0.000 description 11
108060006633 Protein Kinases Proteins 0.000 description 11
125000000217 alkyl group Chemical group 0.000 description 11
229920001223 polyethylene glycol Polymers 0.000 description 11
229960004397 Cyclophosphamide Drugs 0.000 description 10
102100019630 SYK Human genes 0.000 description 10
108010016672 Syk Kinase Proteins 0.000 description 10
239000012043 crude product Substances 0.000 description 10
235000019439 ethyl acetate Nutrition 0.000 description 10
238000000034 method Methods 0.000 description 10
229940021182 non-steroidal anti-inflammatory drugs Drugs 0.000 description 10
XOFYZVNMUHMLCC-ZPOLXVRWSA-N Prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 9
229960004528 Vincristine Drugs 0.000 description 9
206010047802 Waldenstrom's macroglobulinaemias Diseases 0.000 description 9
125000002947 alkylene group Chemical group 0.000 description 9
230000003110 anti-inflammatory Effects 0.000 description 9
WVDDGKGOMKODPV-UHFFFAOYSA-N benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 9
230000015788 innate immune response Effects 0.000 description 9
229960004618 prednisone Drugs 0.000 description 9
230000002829 reduced Effects 0.000 description 9
FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
BZKBCQXYZZXSCO-UHFFFAOYSA-N sodium hydride Chemical compound [H-].[Na+] BZKBCQXYZZXSCO-UHFFFAOYSA-N 0.000 description 9
239000002904 solvent Substances 0.000 description 9
OQANPHBRHBJGNZ-FYJGNVAPSA-N (3E)-6-oxo-3-[[4-(pyridin-2-ylsulfamoyl)phenyl]hydrazinylidene]cyclohexa-1,4-diene-1-carboxylic acid Chemical compound C1=CC(=O)C(C(=O)O)=C\C1=N\NC1=CC=C(S(=O)(=O)NC=2N=CC=CC=2)C=C1 OQANPHBRHBJGNZ-FYJGNVAPSA-N 0.000 description 8
240000001340 Gmelina philippensis Species 0.000 description 8
229960001940 Sulfasalazine Drugs 0.000 description 8
230000003042 antagnostic Effects 0.000 description 8
239000005557 antagonist Substances 0.000 description 8
LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 8
239000000969 carrier Substances 0.000 description 8
238000001514 detection method Methods 0.000 description 8
RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 8
150000002632 lipids Chemical class 0.000 description 8
PMZURENOXWZQFD-UHFFFAOYSA-L na2so4 Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 8
102000005962 receptors Human genes 0.000 description 8
108020003175 receptors Proteins 0.000 description 8
229910052938 sodium sulfate Inorganic materials 0.000 description 8
235000011152 sodium sulphate Nutrition 0.000 description 8
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 8
239000003643 water by type Substances 0.000 description 8
AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 7
206010003246 Arthritis Diseases 0.000 description 7
XWTYSIMOBUGWOL-UHFFFAOYSA-N Bricaril Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 7
VOVIALXJUBGFJZ-VXKMTNQYSA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3O[C@@H](CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-VXKMTNQYSA-N 0.000 description 7
229960004679 Doxorubicin Drugs 0.000 description 7
BPZSYCZIITTYBL-YJYMSZOUSA-N Formoterol Chemical compound C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-YJYMSZOUSA-N 0.000 description 7
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 7
LMOINURANNBYCM-UHFFFAOYSA-N Orciprenaline Chemical compound CC(C)NCC(O)C1=CC(O)=CC(O)=C1 LMOINURANNBYCM-UHFFFAOYSA-N 0.000 description 7
108010001645 Rituximab Proteins 0.000 description 7
102100016864 TYK2 Human genes 0.000 description 7
101700057652 TYK2 Proteins 0.000 description 7
230000004913 activation Effects 0.000 description 7
239000000556 agonist Substances 0.000 description 7
239000002775 capsule Substances 0.000 description 7
229910052799 carbon Inorganic materials 0.000 description 7
LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
238000009472 formulation Methods 0.000 description 7
LHLMOSXCXGLMMN-VVQPYUEFSA-M ipratropium bromide Chemical compound [Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 LHLMOSXCXGLMMN-VVQPYUEFSA-M 0.000 description 7
239000012044 organic layer Substances 0.000 description 7
239000000047 product Substances 0.000 description 7
200000000008 restenosis Diseases 0.000 description 7
229960004641 rituximab Drugs 0.000 description 7
239000000741 silica gel Substances 0.000 description 7
229910002027 silica gel Inorganic materials 0.000 description 7
239000000725 suspension Substances 0.000 description 7
239000003826 tablet Substances 0.000 description 7
238000005160 1H NMR spectroscopy Methods 0.000 description 6
MCGSCOLBFJQGHM-SCZZXKLOSA-N Abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 description 6
GXJABQQUPOEUTA-RDJZCZTQSA-N Bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 6
RZEKVGVHFLEQIL-UHFFFAOYSA-N Celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 6
JCKYGMPEJWAADB-UHFFFAOYSA-N Chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 6
WHTVZRBIWZFKQO-UHFFFAOYSA-N Chloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 6
IAKHMKGGTNLKSZ-INIZCTEOSA-N Colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 6
UREBDLICKHMUKA-CXSFZGCWSA-N Dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 6
102000004190 Enzymes Human genes 0.000 description 6
108090000790 Enzymes Proteins 0.000 description 6
XSFJVAJPIHIPKU-XWCQMRHXSA-N Flunisolide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O XSFJVAJPIHIPKU-XWCQMRHXSA-N 0.000 description 6
VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
XXSMGPRMXLTPCZ-UHFFFAOYSA-N Hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 6
102000014150 Interferons Human genes 0.000 description 6
108010050904 Interferons Proteins 0.000 description 6
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 6
GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 6
NDAUXUAQIAJITI-LBPRGKRZSA-N Levosalbutamol Chemical compound CC(C)(C)NC[C@H](O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-LBPRGKRZSA-N 0.000 description 6
206010061877 Obstructive airways disease Diseases 0.000 description 6
VVNCNSJFMMFHPL-VKHMYHEASA-N Penicillamine Chemical compound CC(C)(S)[C@@H](N)C(O)=O VVNCNSJFMMFHPL-VKHMYHEASA-N 0.000 description 6
OIGNJSKKLXVSLS-VWUMJDOOSA-N Prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 6
NCDNCNXCDXHOMX-XGKFQTDJSA-N Ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 6
229960001852 Saquinavir Drugs 0.000 description 6
QWAXKHKRTORLEM-UGJKXSETSA-N Saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 description 6
229960000278 Theophylline Drugs 0.000 description 6
230000001028 anti-proliferant Effects 0.000 description 6
239000011230 binding agent Substances 0.000 description 6
230000037396 body weight Effects 0.000 description 6
229960001467 bortezomib Drugs 0.000 description 6
229960000590 celecoxib Drugs 0.000 description 6
230000001809 detectable Effects 0.000 description 6
PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
229920002674 hyaluronan Polymers 0.000 description 6
239000008101 lactose Substances 0.000 description 6
229950008204 levosalbutamol Drugs 0.000 description 6
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
230000003000 nontoxic Effects 0.000 description 6
231100000252 nontoxic Toxicity 0.000 description 6
229960005205 prednisolone Drugs 0.000 description 6
238000002360 preparation method Methods 0.000 description 6
238000002953 preparative HPLC Methods 0.000 description 6
229960000311 ritonavir Drugs 0.000 description 6
229960002052 salbutamol Drugs 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
150000003431 steroids Chemical class 0.000 description 6
YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
206010000565 Acquired immunodeficiency syndrome Diseases 0.000 description 5
229940023808 Albuterol Drugs 0.000 description 5
206010003210 Arteriosclerosis Diseases 0.000 description 5
229960002170 Azathioprine Drugs 0.000 description 5
0 C*C(CCC1)c2c1[s]c1c2c(*C)cc(*)n1 Chemical compound C*C(CCC1)c2c1[s]c1c2c(*C)cc(*)n1 0.000 description 5
JYGXADMDTFJGBT-VWUMJDOOSA-N Cortisol Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 5
210000003979 Eosinophils Anatomy 0.000 description 5
XFBVBWWRPKNWHW-UHFFFAOYSA-N Etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 5
229960005293 Etodolac Drugs 0.000 description 5
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 5
229940047124 Interferons Drugs 0.000 description 5
108050006617 Interleukin-1 receptor family Proteins 0.000 description 5
102000003810 Interleukin-18 Human genes 0.000 description 5
108090000171 Interleukin-18 Proteins 0.000 description 5
VHOGYURTWQBHIL-UHFFFAOYSA-N Leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 5
229940063718 Lodine Drugs 0.000 description 5
206010025135 Lupus erythematosus Diseases 0.000 description 5
CMWTZPSULFXXJA-VIFPVBQESA-N Naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 5
108091007929 PDGF receptors Proteins 0.000 description 5
102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 5
239000002202 Polyethylene glycol Substances 0.000 description 5
206010072736 Rheumatic disease Diseases 0.000 description 5
229940003641 Rituxan Drugs 0.000 description 5
102100009534 TNF Human genes 0.000 description 5
229960000237 Vorinostat Drugs 0.000 description 5
WAEXFXRVDQXREF-UHFFFAOYSA-N Vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 5
238000010521 absorption reaction Methods 0.000 description 5
229960001138 acetylsalicylic acid Drugs 0.000 description 5
BSYNRYMUTXBXSQ-UHFFFAOYSA-N aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 5
201000001320 atherosclerosis Diseases 0.000 description 5
239000000812 cholinergic antagonist Substances 0.000 description 5
238000001816 cooling Methods 0.000 description 5
239000002270 dispersing agent Substances 0.000 description 5
NNYBQONXHNTVIJ-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=C1C(C=CC=C1CC)=C1N2 NNYBQONXHNTVIJ-UHFFFAOYSA-N 0.000 description 5
235000013305 food Nutrition 0.000 description 5
230000014509 gene expression Effects 0.000 description 5
239000003276 histone deacetylase inhibitor Substances 0.000 description 5
229960000890 hydrocortisone Drugs 0.000 description 5
229960001680 ibuprofen Drugs 0.000 description 5
238000004519 manufacturing process Methods 0.000 description 5
239000000463 material Substances 0.000 description 5
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
239000002480 mineral oil Substances 0.000 description 5
235000010446 mineral oil Nutrition 0.000 description 5
108010045030 monoclonal antibodies Proteins 0.000 description 5
102000005614 monoclonal antibodies Human genes 0.000 description 5
125000002950 monocyclic group Chemical group 0.000 description 5
229960002009 naproxen Drugs 0.000 description 5
230000037361 pathway Effects 0.000 description 5
239000003757 phosphotransferase inhibitor Substances 0.000 description 5
239000006187 pill Substances 0.000 description 5
108010046141 rilonacept Proteins 0.000 description 5
239000007909 solid dosage form Substances 0.000 description 5
230000000699 topical Effects 0.000 description 5
ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 5
239000001993 wax Substances 0.000 description 5
XQSPYNMVSIKCOC-NTSWFWBYSA-N (2R-cis)-4-amino-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-Pyrimidinone Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1 XQSPYNMVSIKCOC-NTSWFWBYSA-N 0.000 description 4
PMATZTZNYRCHOR-CGLBZJNRSA-N (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17 Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 4
JTEGQNOMFQHVDC-NKWVEPMBSA-N 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-1,2-dihydropyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 4
PJVWKTKQMONHTI-UHFFFAOYSA-N 4-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 4
102000034451 ATPases Human genes 0.000 description 4
108091006096 ATPases Proteins 0.000 description 4
229940022659 Acetaminophen Drugs 0.000 description 4
206010000880 Acute myeloid leukaemia Diseases 0.000 description 4
KHOITXIGCFIULA-UHFFFAOYSA-N Alophen Chemical compound C1=CC(OC(=O)C)=CC=C1C(C=1N=CC=CC=1)C1=CC=C(OC(C)=O)C=C1 KHOITXIGCFIULA-UHFFFAOYSA-N 0.000 description 4
FLZQKRKHLSUHOR-UHFFFAOYSA-N Alosetron Chemical compound CC1=NC=N[C]1CN1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FLZQKRKHLSUHOR-UHFFFAOYSA-N 0.000 description 4
YMARZQAQMVYCKC-OEMFJLHTSA-N Amprenavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 YMARZQAQMVYCKC-OEMFJLHTSA-N 0.000 description 4
AXRYRYVKAWYZBR-GASGPIRDSA-N Atazanavir Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)[C@@H](O)CN(CC=1C=CC(=CC=1)C=1N=CC=CC=1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C1=CC=CC=C1 AXRYRYVKAWYZBR-GASGPIRDSA-N 0.000 description 4
229960004436 Budesonide Drugs 0.000 description 4
239000004215 Carbon black (E152) Substances 0.000 description 4
HYPPXZBJBPSRLK-UHFFFAOYSA-N Co-phenotrope Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCC(C#N)(C=1C=CC=CC=1)C1=CC=CC=C1 HYPPXZBJBPSRLK-UHFFFAOYSA-N 0.000 description 4
108010036949 Cyclosporine Proteins 0.000 description 4
102000004127 Cytokines Human genes 0.000 description 4
108090000695 Cytokines Proteins 0.000 description 4
229960003957 Dexamethasone Drugs 0.000 description 4
CURUTKGFNZGFSE-UHFFFAOYSA-N Dicycloverine Chemical compound C1CCCCC1C1(C(=O)OCCN(CC)CC)CCCCC1 CURUTKGFNZGFSE-UHFFFAOYSA-N 0.000 description 4
XPOQHMRABVBWPR-ZDUSSCGKSA-N Efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 description 4
PYGWGZALEOIKDF-UHFFFAOYSA-N Etravirine Chemical compound CC1=CC(C#N)=CC(C)=C1OC1=NC(NC=2C=CC(=CC=2)C#N)=NC(N)=C1Br PYGWGZALEOIKDF-UHFFFAOYSA-N 0.000 description 4
BQSJTQLCZDPROO-UHFFFAOYSA-N Febuxostat Chemical compound C1=C(C#N)C(OCC(C)C)=CC=C1C1=NC(C)=C(C(O)=O)S1 BQSJTQLCZDPROO-UHFFFAOYSA-N 0.000 description 4
MLBVMOWEQCZNCC-OEMFJLHTSA-N Fosamprenavir Chemical compound C([C@@H]([C@H](OP(O)(O)=O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 MLBVMOWEQCZNCC-OEMFJLHTSA-N 0.000 description 4
101700017615 HSP82 Proteins 0.000 description 4
101700042119 HSP83 Proteins 0.000 description 4
101710023137 HSP90B1 Proteins 0.000 description 4
102000003964 Histone deacetylases Human genes 0.000 description 4
108090000353 Histone deacetylases Proteins 0.000 description 4
KTUFNOKKBVMGRW-UHFFFAOYSA-N Imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 4
CBVCZFGXHXORBI-PXQQMZJSSA-N Indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 description 4
102000019223 Interleukin-1 receptor family Human genes 0.000 description 4
229960001361 Ipratropium Bromide Drugs 0.000 description 4
239000005517 L01XE01 - Imatinib Substances 0.000 description 4
GOTYRUGSSMKFNF-UHFFFAOYSA-N Lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 4
208000007046 Leukemia, Myeloid, Acute Diseases 0.000 description 4
RDOIQAHITMMDAJ-UHFFFAOYSA-N Loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 description 4
229960001571 Loperamide Drugs 0.000 description 4
WGFOBBZOWHGYQH-MXHNKVEKSA-N Lubiprostone Chemical compound O1[C@](C(F)(F)CCCC)(O)CC[C@@H]2[C@@H](CCCCCCC(O)=O)C(=O)C[C@H]21 WGFOBBZOWHGYQH-MXHNKVEKSA-N 0.000 description 4
229960000345 Lubiprostone Drugs 0.000 description 4
101710006465 MOD-E Proteins 0.000 description 4
GSNHKUDZZFZSJB-QYOOZWMWSA-N Maraviroc Chemical compound CC(C)C1=NN=C(C)N1[C@@H]1C[C@H](N2CC[C@H](NC(=O)C3CCC(F)(F)CC3)C=3C=CC=CC=3)CC[C@H]2C1 GSNHKUDZZFZSJB-QYOOZWMWSA-N 0.000 description 4
241001465754 Metazoa Species 0.000 description 4
VHRSUDSXCMQTMA-PJHHCJLFSA-N Methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 4
102000028664 Microtubules Human genes 0.000 description 4
108091022031 Microtubules Proteins 0.000 description 4
210000004688 Microtubules Anatomy 0.000 description 4
229950010895 Midostaurin Drugs 0.000 description 4
KKZJGLLVHKMTCM-UHFFFAOYSA-N Mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 4
229960001156 Mitoxantrone Drugs 0.000 description 4
UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 description 4
ZQPPMHVWECSIRJ-KTKRTIGZSA-N Oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 4
229920000272 Oligonucleotide Polymers 0.000 description 4
206010035653 Pneumoconiosis Diseases 0.000 description 4
208000002098 Purpura, Thrombocytopenic, Idiopathic Diseases 0.000 description 4
108020004532 RAS Proteins 0.000 description 4
CZFFBEXEKNGXKS-UHFFFAOYSA-N Raltegravir Chemical compound O1C(C)=NN=C1C(=O)NC(C)(C)C1=NC(C(=O)NCC=2C=CC(F)=CC=2)=C(O)C(=O)N1C CZFFBEXEKNGXKS-UHFFFAOYSA-N 0.000 description 4
229960004742 Raltegravir Drugs 0.000 description 4
206010038563 Reocclusion Diseases 0.000 description 4
WHBIGIKBNXZKFE-UHFFFAOYSA-N Rescriptor Chemical compound CC(C)NC1=CC=CN=C1N1CCN(C(=O)C=2NC3=CC=C(NS(C)(=O)=O)C=C3C=2)CC1 WHBIGIKBNXZKFE-UHFFFAOYSA-N 0.000 description 4
GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 4
241000580858 Simian-Human immunodeficiency virus Species 0.000 description 4
229960001203 Stavudine Drugs 0.000 description 4
XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 description 4
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
DQHNAVOVODVIMG-UHFFFAOYSA-M Tiotropium bromide Chemical compound [Br-].C1C(C2C3O2)[N+](C)(C)C3CC1OC(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 DQHNAVOVODVIMG-UHFFFAOYSA-M 0.000 description 4
SUJUHGSWHZTSEU-FYBSXPHGSA-N Tipranavir Chemical compound C([C@@]1(CCC)OC(=O)C([C@H](CC)C=2C=C(NS(=O)(=O)C=3N=CC(=CC=3)C(F)(F)F)C=CC=2)=C(O)C1)CC1=CC=CC=C1 SUJUHGSWHZTSEU-FYBSXPHGSA-N 0.000 description 4
GFNANZIMVAIWHM-OBYCQNJPSA-N Triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 4
CXNIUSPIQKWYAI-UHFFFAOYSA-N Xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 4
HBOMLICNUCNMMY-XLPZGREQSA-N Zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 4
229960004748 abacavir Drugs 0.000 description 4
238000007792 addition Methods 0.000 description 4
229960001830 amprenavir Drugs 0.000 description 4
238000002399 angioplasty Methods 0.000 description 4
229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 description 4
229960003277 atazanavir Drugs 0.000 description 4
201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 4
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
238000004166 bioassay Methods 0.000 description 4
230000003182 bronchodilatating Effects 0.000 description 4
UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
229960001265 ciclosporin Drugs 0.000 description 4
238000002648 combination therapy Methods 0.000 description 4
229960000265 cromoglicic acid Drugs 0.000 description 4
125000000753 cycloalkyl group Chemical group 0.000 description 4
229960005107 darunavir Drugs 0.000 description 4
CJBJHOAVZSMMDJ-HEXNFIEUSA-N darunavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1[C@@H]2CCO[C@@H]2OC1)C1=CC=CC=C1 CJBJHOAVZSMMDJ-HEXNFIEUSA-N 0.000 description 4
WREGKURFCTUGRC-POYBYMJQSA-N ddC Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 4
BXZVVICBKDXVGW-NKWVEPMBSA-N ddIno Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 4
229960005319 delavirdine Drugs 0.000 description 4
238000011161 development Methods 0.000 description 4
230000018109 developmental process Effects 0.000 description 4
229960002656 didanosine Drugs 0.000 description 4
235000014113 dietary fatty acids Nutrition 0.000 description 4
239000003085 diluting agent Substances 0.000 description 4
VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 4
238000002651 drug therapy Methods 0.000 description 4
229960003804 efavirenz Drugs 0.000 description 4
229960000366 emtricitabine Drugs 0.000 description 4
239000003995 emulsifying agent Substances 0.000 description 4
229960002062 enfuvirtide Drugs 0.000 description 4
PEASPLKKXBYDKL-FXEVSJAOSA-N enfuvirtide Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(C)=O)[C@@H](C)O)[C@@H](C)CC)C1=CN=CN1 PEASPLKKXBYDKL-FXEVSJAOSA-N 0.000 description 4
229960002049 etravirine Drugs 0.000 description 4
239000000284 extract Substances 0.000 description 4
239000000194 fatty acid Substances 0.000 description 4
229960005101 febuxostat Drugs 0.000 description 4
GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 4
229960002848 formoterol Drugs 0.000 description 4
239000003102 growth factor Substances 0.000 description 4
229920000669 heparin Polymers 0.000 description 4
229960002411 imatinib Drugs 0.000 description 4
229960001936 indinavir Drugs 0.000 description 4
239000003701 inert diluent Substances 0.000 description 4
239000000543 intermediate Substances 0.000 description 4
230000000968 intestinal Effects 0.000 description 4
229960000681 leflunomide Drugs 0.000 description 4
229960004942 lenalidomide Drugs 0.000 description 4
239000007788 liquid Substances 0.000 description 4
229960004710 maraviroc Drugs 0.000 description 4
239000002609 media Substances 0.000 description 4
229940054556 metaproterenol Drugs 0.000 description 4
229960000485 methotrexate Drugs 0.000 description 4
229960004584 methylprednisolone Drugs 0.000 description 4
BMGQWWVMWDBQGC-IIFHNQTCSA-N midostaurin Chemical compound CN([C@H]1[C@H]([C@]2(C)O[C@@H](N3C4=CC=CC=C4C4=C5C(=O)NCC5=C5C6=CC=CC=C6N2C5=C43)C1)OC)C(=O)C1=CC=CC=C1 BMGQWWVMWDBQGC-IIFHNQTCSA-N 0.000 description 4
229960000060 monoclonal antibodies Drugs 0.000 description 4
229960005127 montelukast Drugs 0.000 description 4
230000035772 mutation Effects 0.000 description 4
239000000346 nonvolatile oil Substances 0.000 description 4
230000000414 obstructive Effects 0.000 description 4
239000002674 ointment Substances 0.000 description 4
230000002246 oncogenic Effects 0.000 description 4
229960002657 orciprenaline Drugs 0.000 description 4
MUBZPKHOEPUJKR-UHFFFAOYSA-N oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
RZVAJINKPMORJF-UHFFFAOYSA-N p-acetaminophenol Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 4
229960005489 paracetamol Drugs 0.000 description 4
229960001639 penicillamine Drugs 0.000 description 4
239000003208 petroleum Substances 0.000 description 4
229910052698 phosphorus Inorganic materials 0.000 description 4
229920000642 polymer Polymers 0.000 description 4
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 4
238000001959 radiotherapy Methods 0.000 description 4
108020001180 rasD Proteins 0.000 description 4
230000004044 response Effects 0.000 description 4
229960001886 rilonacept Drugs 0.000 description 4
239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 4
229960004017 salmeterol Drugs 0.000 description 4
239000000375 suspending agent Substances 0.000 description 4
WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 4
229960000838 tipranavir Drugs 0.000 description 4
210000001519 tissues Anatomy 0.000 description 4
DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
239000000080 wetting agent Substances 0.000 description 4
229960000523 zalcitabine Drugs 0.000 description 4
NRUKOCRGYNPUPR-QBPJDGROSA-N (5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-thiophen-2-yl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 3
HMLGSIZOMSVISS-ONJSNURVSA-N (7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 description 3
XTZNCVSCVHTPAI-UHFFFAOYSA-N 2-carboxynaphthalen-1-olate;[2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]-[6-(4-phenylbutoxy)hexyl]azanium Chemical compound C1=CC=CC2=C(O)C(C(=O)O)=CC=C21.C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 XTZNCVSCVHTPAI-UHFFFAOYSA-N 0.000 description 3
GHASVSINZRGABV-UHFFFAOYSA-N 5-flurouricil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 3
RTAPDZBZLSXHQQ-UHFFFAOYSA-N 8-methyl-3,7-dihydropurine-2,6-dione Chemical class N1C(=O)NC(=O)C2=C1N=C(C)N2 RTAPDZBZLSXHQQ-UHFFFAOYSA-N 0.000 description 3
101700006234 AKT1 Proteins 0.000 description 3
229940005497 ANTICHOLINERGIC AGENTS Drugs 0.000 description 3
229940033495 ANTIMALARIALS Drugs 0.000 description 3
206010027654 Allergic conditions Diseases 0.000 description 3
229960003556 Aminophylline Drugs 0.000 description 3
229940098165 Atrovent Drugs 0.000 description 3
208000005783 Autoimmune Thyroiditis Diseases 0.000 description 3
229940064856 Azulfidine Drugs 0.000 description 3
206010060945 Bacterial infection Diseases 0.000 description 3
229940092703 Beclomethasone Dipropionate Drugs 0.000 description 3
108010005144 Bevacizumab Proteins 0.000 description 3
LERNTVKEWCAPOY-VOGVJGKGSA-N C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 Chemical compound C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 LERNTVKEWCAPOY-VOGVJGKGSA-N 0.000 description 3
229960004630 Chlorambucil Drugs 0.000 description 3
229960003677 Chloroquine Drugs 0.000 description 3
229920001268 Cholestyramine Polymers 0.000 description 3
CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
229940103439 Dulera Drugs 0.000 description 3
101700033006 EGF Proteins 0.000 description 3
102100010813 EGF Human genes 0.000 description 3
102000001301 EGF receptors Human genes 0.000 description 3
108060006698 EGF receptors Proteins 0.000 description 3
241000196324 Embryophyta Species 0.000 description 3
229960002949 Fluorouracil Drugs 0.000 description 3
229940107791 Foradil Drugs 0.000 description 3
206010066476 Haematological malignancy Diseases 0.000 description 3
229960004171 Hydroxychloroquine Drugs 0.000 description 3
229960000908 Idarubicin Drugs 0.000 description 3
XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin hydrochloride Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 3
229940073062 Imuran Drugs 0.000 description 3
206010061255 Ischaemia Diseases 0.000 description 3
229940063725 Leukeran Drugs 0.000 description 3
229940087612 Levalbuterol Drugs 0.000 description 3
241000124008 Mammalia Species 0.000 description 3
229940103178 Maxair Drugs 0.000 description 3
229960001664 Mometasone Drugs 0.000 description 3
208000010125 Myocardial Infarction Diseases 0.000 description 3
QAGYKUNXZHXKMR-HKWSIXNMSA-N Nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 description 3
210000001178 Neural Stem Cells Anatomy 0.000 description 3
206010029592 Non-Hodgkin's lymphomas Diseases 0.000 description 3
VQDBNKDJNJQRDG-UHFFFAOYSA-N Pirbuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=N1 VQDBNKDJNJQRDG-UHFFFAOYSA-N 0.000 description 3
229960004994 Pirbuterol acetate Drugs 0.000 description 3
229940072689 Plaquenil Drugs 0.000 description 3
108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 3
102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 3
229940063566 Proventil Drugs 0.000 description 3
229940014063 Qvar Drugs 0.000 description 3
229940061969 Rheumatrex Drugs 0.000 description 3
PYWVYCXTNDRMGF-UHFFFAOYSA-N Rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 3
102000000505 Ribonucleotide Reductases Human genes 0.000 description 3
108010041388 Ribonucleotide Reductases Proteins 0.000 description 3
229960005018 Salmeterol xinafoate Drugs 0.000 description 3
229940090585 Serevent Drugs 0.000 description 3
229940001147 Singulair Drugs 0.000 description 3
QFJCIRLUMZQUOT-HPLJOQBZSA-N Sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 3
229940046810 Spiriva Drugs 0.000 description 3
CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 3
229940035073 Symbicort Drugs 0.000 description 3
102000004591 Telomerase Human genes 0.000 description 3
108010017842 Telomerase Proteins 0.000 description 3
229960001278 Teniposide Drugs 0.000 description 3
229960005105 Terbutaline Sulfate Drugs 0.000 description 3
229940089554 Theo-24 Drugs 0.000 description 3
229960002117 Triamcinolone Acetonide Drugs 0.000 description 3
YNDXUCZADRHECN-JNQJZLCISA-N Triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 3
229940089541 Uniphyl Drugs 0.000 description 3
102000016548 Vascular Endothelial Growth Factor Receptor-1 Human genes 0.000 description 3
108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 3
229940070384 Ventolin Drugs 0.000 description 3
229940061637 Xopenex Drugs 0.000 description 3
HGMSJMJPXGGEBP-UHFFFAOYSA-N [4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium Chemical compound C1=CC(CC)=CC=C1C(C)CCC1=CC=C([N+](C)(C)C)C=C1 HGMSJMJPXGGEBP-UHFFFAOYSA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
QSXMZJGGEWYVCN-UHFFFAOYSA-N acetic acid;6-[2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)pyridin-3-ol Chemical compound CC(O)=O.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=N1 QSXMZJGGEWYVCN-UHFFFAOYSA-N 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
239000008186 active pharmaceutical agent Substances 0.000 description 3
235000010443 alginic acid Nutrition 0.000 description 3
229920000615 alginic acid Polymers 0.000 description 3
229910052784 alkaline earth metal Inorganic materials 0.000 description 3
125000003342 alkenyl group Chemical group 0.000 description 3
125000004450 alkenylene group Chemical group 0.000 description 3
QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 3
229960004238 anakinra Drugs 0.000 description 3
230000001772 anti-angiogenic Effects 0.000 description 3
230000001078 anti-cholinergic Effects 0.000 description 3
230000001833 anti-estrogenic Effects 0.000 description 3
230000000078 anti-malarial Effects 0.000 description 3
239000000739 antihistaminic agent Substances 0.000 description 3
239000003430 antimalarial agent Substances 0.000 description 3
239000003886 aromatase inhibitor Substances 0.000 description 3
239000002585 base Substances 0.000 description 3
229950000210 beclometasone dipropionate Drugs 0.000 description 3
235000019445 benzyl alcohol Nutrition 0.000 description 3
229960000397 bevacizumab Drugs 0.000 description 3
239000012267 brine Substances 0.000 description 3
235000019437 butane-1,3-diol Nutrition 0.000 description 3
PUPZLCDOIYMWBV-UHFFFAOYSA-N butylene glycol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 3
OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
150000001721 carbon Chemical class 0.000 description 3
239000001768 carboxy methyl cellulose Substances 0.000 description 3
230000015556 catabolic process Effects 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
230000003111 delayed Effects 0.000 description 3
230000001419 dependent Effects 0.000 description 3
201000010870 diseases of metabolism Diseases 0.000 description 3
239000006185 dispersion Substances 0.000 description 3
239000000839 emulsion Substances 0.000 description 3
230000002708 enhancing Effects 0.000 description 3
239000000328 estrogen antagonist Substances 0.000 description 3
235000019441 ethanol Nutrition 0.000 description 3
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
150000004665 fatty acids Chemical class 0.000 description 3
239000000945 filler Substances 0.000 description 3
238000001914 filtration Methods 0.000 description 3
229960000676 flunisolide Drugs 0.000 description 3
239000008187 granular material Substances 0.000 description 3
230000036571 hydration Effects 0.000 description 3
238000006703 hydration reaction Methods 0.000 description 3
UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
230000035874 hyperreactivity Effects 0.000 description 3
230000036039 immunity Effects 0.000 description 3
230000001939 inductive effect Effects 0.000 description 3
239000003446 ligand Substances 0.000 description 3
239000000314 lubricant Substances 0.000 description 3
235000019359 magnesium stearate Nutrition 0.000 description 3
GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 3
229960001428 mercaptopurine Drugs 0.000 description 3
239000002207 metabolite Substances 0.000 description 3
230000000051 modifying Effects 0.000 description 3
QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 description 3
125000002757 morpholinyl group Chemical group 0.000 description 3
229960000884 nelfinavir Drugs 0.000 description 3
239000002773 nucleotide Substances 0.000 description 3
125000003729 nucleotide group Chemical group 0.000 description 3
230000008506 pathogenesis Effects 0.000 description 3
235000019271 petrolatum Nutrition 0.000 description 3
235000021317 phosphate Nutrition 0.000 description 3
238000006366 phosphorylation reaction Methods 0.000 description 3
230000000865 phosphorylative Effects 0.000 description 3
125000004193 piperazinyl group Chemical group 0.000 description 3
125000003386 piperidinyl group Chemical group 0.000 description 3
239000000843 powder Substances 0.000 description 3
230000002335 preservative Effects 0.000 description 3
239000003755 preservative agent Substances 0.000 description 3
239000003207 proteasome inhibitor Substances 0.000 description 3
125000000719 pyrrolidinyl group Chemical group 0.000 description 3
238000010992 reflux Methods 0.000 description 3
230000019491 signal transduction Effects 0.000 description 3
229960002930 sirolimus Drugs 0.000 description 3
239000008247 solid mixture Substances 0.000 description 3
241000894007 species Species 0.000 description 3
239000005720 sucrose Substances 0.000 description 3
239000000829 suppository Substances 0.000 description 3
125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 3
229940110309 tiotropium Drugs 0.000 description 3
229960000257 tiotropium bromide Drugs 0.000 description 3
239000005483 tyrosine kinase inhibitor Substances 0.000 description 3
WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 2
ZROHGHOFXNOHSO-BNTLRKBRSA-L (1R,2R)-cyclohexane-1,2-diamine;oxalate;platinum(2+) Chemical compound [H][N]([C@@H]1CCCC[C@H]1[N]1([H])[H])([H])[Pt]11OC(=O)C(=O)O1 ZROHGHOFXNOHSO-BNTLRKBRSA-L 0.000 description 2
STUWGJZDJHPWGZ-LBPRGKRZSA-N (2S)-1-N-[4-methyl-5-[2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl]-1,3-thiazol-2-yl]pyrrolidine-1,2-dicarboxamide Chemical compound S1C(C=2C=C(N=CC=2)C(C)(C)C(F)(F)F)=C(C)N=C1NC(=O)N1CCC[C@H]1C(N)=O STUWGJZDJHPWGZ-LBPRGKRZSA-N 0.000 description 2
OHJKXVLJWUPWQG-IUYNYSEKSA-J (4S,6R)-6-[(2R,4R)-4,6-dihydroxy-5-(sulfonatoamino)-2-(sulfonatooxymethyl)oxan-3-yl]oxy-3,4-dihydroxy-5-sulfonatooxyoxane-2-carboxylate Chemical compound O[C@@H]1C(NS([O-])(=O)=O)C(O)O[C@H](COS([O-])(=O)=O)C1O[C@H]1C(OS([O-])(=O)=O)[C@@H](O)C(O)C(C([O-])=O)O1 OHJKXVLJWUPWQG-IUYNYSEKSA-J 0.000 description 2
VWUXBMIQPBEWFH-WCCTWKNTSA-N (7R,8R,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 2
UMGQVUWXNOJOSJ-KMHUVPDISA-N (E)-2-cyano-3-(3,4-dihydroxyphenyl)-N-[(1R)-1-phenylethyl]prop-2-enamide Chemical compound N([C@H](C)C=1C=CC=CC=1)C(=O)C(\C#N)=C\C1=CC=C(O)C(O)=C1 UMGQVUWXNOJOSJ-KMHUVPDISA-N 0.000 description 2
YJZSUCFGHXQWDM-UHFFFAOYSA-N 1-adamantyl 4-[(2,5-dihydroxyphenyl)methylamino]benzoate Chemical compound OC1=CC=C(O)C(CNC=2C=CC(=CC=2)C(=O)OC23CC4CC(CC(C4)C2)C3)=C1 YJZSUCFGHXQWDM-UHFFFAOYSA-N 0.000 description 2
KUFRQPKVAWMTJO-LMZWQJSESA-N 17-Dimethylaminoethylamino-17-demethoxygeldanamycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C1C2=O KUFRQPKVAWMTJO-LMZWQJSESA-N 0.000 description 2
BVDRUCCQKHGCRX-UHFFFAOYSA-N 2,3-dihydroxypropyl formate Chemical compound OCC(O)COC=O BVDRUCCQKHGCRX-UHFFFAOYSA-N 0.000 description 2
CGBJSGAELGCMKE-UHFFFAOYSA-N 2,4-difluoro-N-[2-methoxy-5-(4-pyridazin-4-ylquinolin-6-yl)pyridin-3-yl]benzenesulfonamide Chemical compound COC1=NC=C(C=2C=C3C(C=4C=NN=CC=4)=CC=NC3=CC=2)C=C1NS(=O)(=O)C1=CC=C(F)C=C1F CGBJSGAELGCMKE-UHFFFAOYSA-N 0.000 description 2
VTJXFTPMFYAJJU-UHFFFAOYSA-N 2-[(3,4-dihydroxyphenyl)methylidene]propanedinitrile Chemical compound OC1=CC=C(C=C(C#N)C#N)C=C1O VTJXFTPMFYAJJU-UHFFFAOYSA-N 0.000 description 2
UJULZCJPGRVEEO-UHFFFAOYSA-N 2-chlorocyclopentene-1-carbaldehyde Chemical compound ClC1=C(C=O)CCC1 UJULZCJPGRVEEO-UHFFFAOYSA-N 0.000 description 2
LMWBCTADNYACQV-UHFFFAOYSA-N 2H-pyrrole Chemical group C1C=C=C=N1 LMWBCTADNYACQV-UHFFFAOYSA-N 0.000 description 2
NHFDRBXTEDBWCZ-ZROIWOOFSA-N 3-[2,4-dimethyl-5-[(Z)-(2-oxo-1H-indol-3-ylidene)methyl]-1H-pyrrol-3-yl]propanoic acid Chemical compound OC(=O)CCC1=C(C)NC(\C=C/2C3=CC=CC=C3NC\2=O)=C1C NHFDRBXTEDBWCZ-ZROIWOOFSA-N 0.000 description 2
BGLPECHZZQDNCD-UHFFFAOYSA-N 4-(cyclopropylamino)-2-[4-(4-ethylsulfonylpiperazin-1-yl)anilino]pyrimidine-5-carboxamide Chemical compound C1CN(S(=O)(=O)CC)CCN1C(C=C1)=CC=C1NC1=NC=C(C(N)=O)C(NC2CC2)=N1 BGLPECHZZQDNCD-UHFFFAOYSA-N 0.000 description 2
HGVNLRPZOWWDKD-UHFFFAOYSA-N 4-[4-[2-(difluoromethyl)benzimidazol-1-yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl]morpholine Chemical compound FC(F)C1=NC2=CC=CC=C2N1C(N=1)=NC(N2CCOCC2)=NC=1N1CCOCC1 HGVNLRPZOWWDKD-UHFFFAOYSA-N 0.000 description 2
XSFUFVBXPLWNBK-UHFFFAOYSA-N 5,6-dihydro-4H-cyclopenta[b]thiophene-2-carboxylic acid Chemical compound C1CCC2=C1C=C(C(=O)O)S2 XSFUFVBXPLWNBK-UHFFFAOYSA-N 0.000 description 2
102100001248 AKT1 Human genes 0.000 description 2
102100011141 ALK Human genes 0.000 description 2
108010061171 Abatacept Proteins 0.000 description 2
241000238876 Acari Species 0.000 description 2
229940119059 Actemra Drugs 0.000 description 2
108010007562 Adalimumab Proteins 0.000 description 2
OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 2
229960004343 Alendronic acid Drugs 0.000 description 2
IKYJCHYORFJFRR-UHFFFAOYSA-N Alexa Fluor 350 Chemical compound O=C1OC=2C=C(N)C(S(O)(=O)=O)=CC=2C(C)=C1CC(=O)ON1C(=O)CCC1=O IKYJCHYORFJFRR-UHFFFAOYSA-N 0.000 description 2
WHVNXSBKJGAXKU-UHFFFAOYSA-N Alexa Fluor 532 Chemical compound [H+].[H+].CC1(C)C(C)NC(C(=C2OC3=C(C=4C(C(C(C)N=4)(C)C)=CC3=3)S([O-])(=O)=O)S([O-])(=O)=O)=C1C=C2C=3C(C=C1)=CC=C1C(=O)ON1C(=O)CCC1=O WHVNXSBKJGAXKU-UHFFFAOYSA-N 0.000 description 2
ZAINTDRBUHCDPZ-UHFFFAOYSA-M Alexa Fluor 546 Chemical compound [H+].[Na+].CC1CC(C)(C)NC(C(=C2OC3=C(C4=NC(C)(C)CC(C)C4=CC3=3)S([O-])(=O)=O)S([O-])(=O)=O)=C1C=C2C=3C(C(=C(Cl)C=1Cl)C(O)=O)=C(Cl)C=1SCC(=O)NCCCCCC(=O)ON1C(=O)CCC1=O ZAINTDRBUHCDPZ-UHFFFAOYSA-M 0.000 description 2
208000002205 Allergic Conjunctivitis Diseases 0.000 description 2
206010048594 Allergic granulomatous angiitis Diseases 0.000 description 2
OFCNXPDARWKPPY-UHFFFAOYSA-N Allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 2
229960003437 Aminoglutethimide Drugs 0.000 description 2
ROBVIMPUHSLWNV-UHFFFAOYSA-N Aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 2
229940040386 Amitiza Drugs 0.000 description 2
YBBLVLTVTVSKRW-UHFFFAOYSA-N Anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 2
206010002383 Angina pectoris Diseases 0.000 description 2
208000010123 Anthracosis Diseases 0.000 description 2
208000008637 Anti-Glomerular Basement Membrane Disease Diseases 0.000 description 2
229940006211 Anticholinergic mydriatics and cycloplegics Drugs 0.000 description 2
229940065524 Anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 2
229940030139 Aptivus Drugs 0.000 description 2
229940059756 Arava Drugs 0.000 description 2
229940094361 Arcalyst Drugs 0.000 description 2
BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 2
206010003441 Asbestosis Diseases 0.000 description 2
206010003557 Asthma exercise induced Diseases 0.000 description 2
XHVAWZZCDCWGBK-WYRLRVFGSA-M Aurothioglucose Chemical compound OC[C@H]1O[C@H](S[Au])[C@H](O)[C@@H](O)[C@@H]1O XHVAWZZCDCWGBK-WYRLRVFGSA-M 0.000 description 2
JOGKUKXHTYWRGZ-UHFFFAOYSA-N BEZ235 Chemical compound O=C1N(C)C2=CN=C3C=CC(C=4C=C5C=CC=CC5=NC=4)=CC3=C2N1C1=CC=C(C(C)(C)C#N)C=C1 JOGKUKXHTYWRGZ-UHFFFAOYSA-N 0.000 description 2
CWHUFRVAEUJCEF-UHFFFAOYSA-N BKM120 Chemical compound C1=NC(N)=CC(C(F)(F)F)=C1C1=CC(N2CCOCC2)=NC(N2CCOCC2)=N1 CWHUFRVAEUJCEF-UHFFFAOYSA-N 0.000 description 2
206010004161 Basedow's disease Diseases 0.000 description 2
229940090012 Bentyl Drugs 0.000 description 2
SESFRYSPDFLNCH-UHFFFAOYSA-N Benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
230000036912 Bioavailability Effects 0.000 description 2
229940112871 Bisphosphonate drugs affecting bone structure and mineralization Drugs 0.000 description 2
241001674044 Blattodea Species 0.000 description 2
210000004369 Blood Anatomy 0.000 description 2
206010005949 Bone cancer Diseases 0.000 description 2
208000000409 Breast Neoplasms Diseases 0.000 description 2
206010006458 Bronchitis chronic Diseases 0.000 description 2
206010006473 Bronchopulmonary aspergillosis Diseases 0.000 description 2
229950003628 Buparlisib Drugs 0.000 description 2
208000007596 Byssinosis Diseases 0.000 description 2
102100012080 CCR5 Human genes 0.000 description 2
101700043583 CCR5 Proteins 0.000 description 2
102100006400 CSF2 Human genes 0.000 description 2
241001164374 Calyx Species 0.000 description 2
VSJKWCGYPAHWDS-FQEVSTJZSA-N Camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 2
GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 2
229960004117 Capecitabine Drugs 0.000 description 2
229960004562 Carboplatin Drugs 0.000 description 2
OLESAACUTLOWQZ-UHFFFAOYSA-L Carboplatin Chemical compound O=C1O[Pt]([N]([H])([H])[H])([N]([H])([H])[H])OC(=O)C11CCC1 OLESAACUTLOWQZ-UHFFFAOYSA-L 0.000 description 2
229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
206010007559 Cardiac failure congestive Diseases 0.000 description 2
208000006029 Cardiomegaly Diseases 0.000 description 2
108010070202 Certolizumab Pegol Proteins 0.000 description 2
102000019034 Chemokines Human genes 0.000 description 2
108010012236 Chemokines Proteins 0.000 description 2
208000007451 Chronic Bronchitis Diseases 0.000 description 2
208000006344 Churg-Strauss Syndrome Diseases 0.000 description 2
229940090100 Cimzia Drugs 0.000 description 2
229960002286 Clodronic Acid Drugs 0.000 description 2
ACSIXWWBWUQEHA-UHFFFAOYSA-N Clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 description 2
229940002157 Colcrys Drugs 0.000 description 2
229940014461 Combivir Drugs 0.000 description 2
208000010247 Contact Dermatitis Diseases 0.000 description 2
229920002261 Corn starch Polymers 0.000 description 2
MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 2
229940072645 Coumadin Drugs 0.000 description 2
229940088900 Crixivan Drugs 0.000 description 2
229940120894 Cromolyn Sodium Drugs 0.000 description 2
229940064774 Cuprimine Drugs 0.000 description 2
229940119017 Cyclosporine Drugs 0.000 description 2
STQGQHZAVUOBTE-VGBVRHCVSA-N DAUNOMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 2
229960000975 Daunorubicin Drugs 0.000 description 2
229940026692 Decadron Drugs 0.000 description 2
229940075911 Depen Drugs 0.000 description 2
206010012442 Dermatitis contact Diseases 0.000 description 2
229960004833 Dexamethasone phosphate Drugs 0.000 description 2
229940120131 Dicyclomine Drugs 0.000 description 2
229960002777 Dicycloverine Drugs 0.000 description 2
ZDZOTLJHXYCWBA-VCVYQWHSSA-N Docetaxel Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 2
229940099198 Dulcolax Drugs 0.000 description 2
208000000059 Dyspnea Diseases 0.000 description 2
206010013975 Dyspnoeas Diseases 0.000 description 2
229960001904 EPIRUBICIN Drugs 0.000 description 2
AOJJSUZBOXZQNB-VTZDEGQISA-N EPIRUBICIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 2
102100016692 ESR1 Human genes 0.000 description 2
206010014561 Emphysema Diseases 0.000 description 2
229940001018 Emtriva Drugs 0.000 description 2
229940073621 Enbrel Drugs 0.000 description 2
108010032976 Enfuvirtide Proteins 0.000 description 2
208000003401 Eosinophilic Granuloma Diseases 0.000 description 2
229940072253 Epivir Drugs 0.000 description 2
229940019131 Epzicom Drugs 0.000 description 2
229960001433 Erlotinib Drugs 0.000 description 2
AAKJLRGGTJKAMG-UHFFFAOYSA-N Erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 2
229960003399 Estrone Drugs 0.000 description 2
108010008165 Etanercept Proteins 0.000 description 2
229960005420 Etoposide Drugs 0.000 description 2
VJJPUSNTGOMMGY-MRVIYFEKSA-N Etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
230000036826 Excretion Effects 0.000 description 2
208000004657 Exercise-Induced Asthma Diseases 0.000 description 2
229950011548 FADROZOLE Drugs 0.000 description 2
102000027757 FGF receptors Human genes 0.000 description 2
108091008101 FGF receptors Proteins 0.000 description 2
101710009074 FLT3 Proteins 0.000 description 2
CLPFFLWZZBQMAO-UHFFFAOYSA-N Fadrozole Chemical compound C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 description 2
102000018233 Fibroblast growth factor family Human genes 0.000 description 2
108050007372 Fibroblast growth factor family Proteins 0.000 description 2
OSVMTWJCGUFAOD-KZQROQTASA-N Formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 description 2
229960002258 Fulvestrant Drugs 0.000 description 2
229940099052 Fuzeon Drugs 0.000 description 2
XGALLCVXEZPNRQ-UHFFFAOYSA-N Gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 2
SDUQYLNIPVEERB-QPPQHZFASA-N Gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 2
102400000932 Gonadoliberin-1 Human genes 0.000 description 2
108010084340 Gonadotropin-Releasing Hormone Proteins 0.000 description 2
206010018620 Goodpasture's syndrome Diseases 0.000 description 2
108010069236 Goserelin Proteins 0.000 description 2
229960002913 Goserelin Drugs 0.000 description 2
BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 2
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
208000003807 Graves Disease Diseases 0.000 description 2
208000002183 Guillain-Barre Syndrome Diseases 0.000 description 2
102100003684 HPSE Human genes 0.000 description 2
210000004209 Hair Anatomy 0.000 description 2
229960002897 Heparin Drugs 0.000 description 2
ZFGMDIBRIDKWMY-PASTXAENSA-N Heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 2
241000238631 Hexapoda Species 0.000 description 2
DNXHEGUUPJUMQT-CBZIJGRNSA-N Hiestrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 2
241000282412 Homo Species 0.000 description 2
229940048921 Humira Drugs 0.000 description 2
229940018991 Hyalgan Drugs 0.000 description 2
KIUKXJAPPMFGSW-MNSSHETKSA-N Hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 2
FDGQSTZJBFJUBT-UHFFFAOYSA-N Hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
108010031794 IGF Type 1 Receptor Proteins 0.000 description 2
102100014263 IGF1R Human genes 0.000 description 2
208000004546 IRAK4 Deficiency Diseases 0.000 description 2
229960003445 Idelalisib Drugs 0.000 description 2
HOMGKSMUEGBAAB-UHFFFAOYSA-N Ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 2
229960001101 Ifosfamide Drugs 0.000 description 2
208000001718 Immediate Hypersensitivity Diseases 0.000 description 2
229940095970 Imodium Drugs 0.000 description 2
206010061217 Infestation Diseases 0.000 description 2
108010053490 Infliximab Proteins 0.000 description 2
229940102223 Injectable Solution Drugs 0.000 description 2
229940102213 Injectable Suspension Drugs 0.000 description 2
RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
229940115474 Intelence Drugs 0.000 description 2
102000004557 Interleukin-18 Receptors Human genes 0.000 description 2
108010017537 Interleukin-18 Receptors Proteins 0.000 description 2
102000004890 Interleukin-8 Human genes 0.000 description 2
108090001007 Interleukin-8 Proteins 0.000 description 2
229940088976 Invirase Drugs 0.000 description 2
UWKQSNNFCGGAFS-XIFFEERXSA-N Irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 2
206010061256 Ischaemic stroke Diseases 0.000 description 2
229940111682 Isentress Drugs 0.000 description 2
KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 description 2
229940112586 Kaletra Drugs 0.000 description 2
229940054136 Kineret Drugs 0.000 description 2
229960001627 Lamivudine Drugs 0.000 description 2
229940033984 Lamivudine / Zidovudine Drugs 0.000 description 2
206010069698 Langerhans' cell histiocytosis Diseases 0.000 description 2
229920000126 Latex Polymers 0.000 description 2
HPJKCIUCZWXJDR-UHFFFAOYSA-N Letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 2
208000008456 Leukemia, Myelogenous, Chronic, BCR-ABL Positive Diseases 0.000 description 2
229940113354 Lexiva Drugs 0.000 description 2
201000009324 Loeffler syndrome Diseases 0.000 description 2
229940087973 Lomotil Drugs 0.000 description 2
229940060963 Lotronex Drugs 0.000 description 2
101700064507 MARK2 Proteins 0.000 description 2
102100000541 MARK2 Human genes 0.000 description 2
VTHJTEIRLNZDEV-UHFFFAOYSA-L Magnesium hydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 2
102000002274 Matrix Metalloproteinases Human genes 0.000 description 2
108010000684 Matrix Metalloproteinases Proteins 0.000 description 2
KBOPZPXVLCULAV-UHFFFAOYSA-N Mesalazine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 2
FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 2
229940060946 Miralax Drugs 0.000 description 2
229940090001 Myochrysine Drugs 0.000 description 2
XGXNTJHZPBRBHJ-UHFFFAOYSA-N N-phenylpyrimidin-2-amine Chemical class N=1C=CC=NC=1NC1=CC=CC=C1 XGXNTJHZPBRBHJ-UHFFFAOYSA-N 0.000 description 2
208000009025 Nervous System Disease Diseases 0.000 description 2
206010029305 Neurological disorder Diseases 0.000 description 2
229960000689 Nevirapine Drugs 0.000 description 2
NQDJXKOVJZTUJA-UHFFFAOYSA-N Nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 description 2
DLGOEMSEDOSKAD-UHFFFAOYSA-N Nitrumon Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 2
229940042402 Non-nucleoside reverse transcriptase inhibitors Drugs 0.000 description 2
229940072250 Norvir Drugs 0.000 description 2
208000007892 Occupational Asthma Diseases 0.000 description 2
239000005642 Oleic acid Substances 0.000 description 2
229960000470 Omalizumab Drugs 0.000 description 2
108010029597 Omalizumab Proteins 0.000 description 2
229940035567 Orencia Drugs 0.000 description 2
229960001592 Paclitaxel Drugs 0.000 description 2
WRUUGTRCQOWXEG-UHFFFAOYSA-N Pamidronic acid Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 2
VLTRZXGMWDSKGL-UHFFFAOYSA-N Perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
206010034695 Pernicious anaemia Diseases 0.000 description 2
229940066842 Petrolatum Drugs 0.000 description 2
239000004264 Petrolatum Substances 0.000 description 2
XHXFXVLFKHQFAL-UHFFFAOYSA-N Phosphoryl chloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
LFSXCDWNBUNEEM-UHFFFAOYSA-N Phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 2
231100000614 Poison Toxicity 0.000 description 2
229920001451 Polypropylene glycol Polymers 0.000 description 2
229940068586 Prezista Drugs 0.000 description 2
DBABZHXKTCFAPX-UHFFFAOYSA-N Probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 2
229960004063 Propylene glycol Drugs 0.000 description 2
102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 2
108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 2
108010029485 Protein Isoforms Proteins 0.000 description 2
102000001708 Protein Isoforms Human genes 0.000 description 2
102000003923 Protein Kinase C Human genes 0.000 description 2
108090000315 Protein Kinase C Proteins 0.000 description 2
102000009516 Protein-Serine-Threonine Kinases Human genes 0.000 description 2
108010009341 Protein-Serine-Threonine Kinases Proteins 0.000 description 2
102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
208000010378 Pulmonary Embolism Diseases 0.000 description 2
229960002119 Raloxifene Hydrochloride Drugs 0.000 description 2
206010038294 Reiter's syndrome Diseases 0.000 description 2
229940116176 Remicade Drugs 0.000 description 2
208000006265 Renal Cell Carcinoma Diseases 0.000 description 2
229940063627 Rescriptor Drugs 0.000 description 2
229940064914 Retrovir Drugs 0.000 description 2
229940120975 Revlimid Drugs 0.000 description 2
229940107904 Reyataz Drugs 0.000 description 2
229940063638 Ridaura Drugs 0.000 description 2
IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 description 2
OGYAHWFUQFIKFX-UHFFFAOYSA-N S1C(=CC2=C1N=CC=C2N)N Chemical compound S1C(=CC2=C1N=CC=C2N)N OGYAHWFUQFIKFX-UHFFFAOYSA-N 0.000 description 2
229940063122 Sandimmune Drugs 0.000 description 2
HZLFFNCLTRVYJG-WWGOJCOQSA-N Saridegib Chemical compound C([C@@]1(CC(C)=C2C3)O[C@@H]4C[C@H](C)CN[C@H]4[C@H]1C)C[C@H]2[C@H]1[C@H]3[C@@]2(C)CC[C@@H](NS(C)(=O)=O)C[C@H]2CC1 HZLFFNCLTRVYJG-WWGOJCOQSA-N 0.000 description 2
229940031307 Selzentry Drugs 0.000 description 2
229940063651 Senokot Drugs 0.000 description 2
206010040070 Septic shock Diseases 0.000 description 2
208000004003 Siderosis Diseases 0.000 description 2
229940068638 Simponi Drugs 0.000 description 2
102000013380 Smoothened Receptor Human genes 0.000 description 2
108010090739 Smoothened Receptor Proteins 0.000 description 2
102000011096 Somatostatin receptor family Human genes 0.000 description 2
108050001286 Somatostatin receptor family Proteins 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
HKSZLNNOFSGOKW-FYTWVXJKSA-N Staurosporine Chemical class C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 2
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
229940054565 Sustiva Drugs 0.000 description 2
229940036220 Synvisc Drugs 0.000 description 2
101710040537 TNF Proteins 0.000 description 2
102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 2
108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 2
108060008443 TPPP Proteins 0.000 description 2
QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 2
229960001603 Tamoxifen Drugs 0.000 description 2
NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
229950008160 Tanezumab Drugs 0.000 description 2
BPEGJWRSRHCHSN-UHFFFAOYSA-N Temodal Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 2
SGOIRFVFHAKUTI-ZCFIWIBFSA-N Tenofovir Chemical compound N1=CN=C2N(C[C@@H](C)OCP(O)(O)=O)C=NC2=C1N SGOIRFVFHAKUTI-ZCFIWIBFSA-N 0.000 description 2
229960004556 Tenofovir Drugs 0.000 description 2
229960003604 Testosterone Drugs 0.000 description 2
DKJJVAGXPKPDRL-UHFFFAOYSA-N Tiludronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)SC1=CC=C(Cl)C=C1 DKJJVAGXPKPDRL-UHFFFAOYSA-N 0.000 description 2
239000004012 Tofacitinib Substances 0.000 description 2
239000000365 Topoisomerase I Inhibitor Substances 0.000 description 2
239000000317 Topoisomerase II Inhibitor Substances 0.000 description 2
UCFGDBYHRUNTLO-QHCPKHFHSA-N Topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 2
108010010691 Trastuzumab Proteins 0.000 description 2
YATVXQQJLKIPSI-VETFBQQWSA-N Trizivir Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)SC1.O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1.C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 YATVXQQJLKIPSI-VETFBQQWSA-N 0.000 description 2
229940111527 Trizivir Drugs 0.000 description 2
206010065258 Tropical eosinophilia Diseases 0.000 description 2
206010045240 Type I hypersensitivity Diseases 0.000 description 2
229940063477 Uloric Drugs 0.000 description 2
102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 description 2
108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
229940099039 Velcade Drugs 0.000 description 2
206010047249 Venous thrombosis Diseases 0.000 description 2
229940108652 Videx Drugs 0.000 description 2
229960003048 Vinblastine Drugs 0.000 description 2
HOFQVRTUGATRFI-XQKSVPLYSA-N Vinblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 HOFQVRTUGATRFI-XQKSVPLYSA-N 0.000 description 2
229960004982 Vinblastine Sulfate Drugs 0.000 description 2
229960002110 Vincristine Sulfate Drugs 0.000 description 2
AQTQHPDCURKLKT-PNYVAJAMSA-N Vincristine sulfate Chemical compound OS(O)(=O)=O.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 AQTQHPDCURKLKT-PNYVAJAMSA-N 0.000 description 2
229940023080 Viracept Drugs 0.000 description 2
229940098802 Viramune Drugs 0.000 description 2
229940109657 Viread Drugs 0.000 description 2
229960005080 Warfarin Drugs 0.000 description 2
206010047924 Wheezing Diseases 0.000 description 2
229940099073 Xolair Drugs 0.000 description 2
229940087450 Zerit Drugs 0.000 description 2
229940052255 Ziagen Drugs 0.000 description 2
229960002555 Zidovudine Drugs 0.000 description 2
XOOUIPVCVHRTMJ-UHFFFAOYSA-L Zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 2
XRASPMIURGNCCH-UHFFFAOYSA-N Zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 description 2
QTQAWLPCGQOSGP-DVKIRIBLSA-N [(3R,5R,6S,7R,8E,10R,11R,12E,14E)-6-hydroxy-5,11,21-trimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate Chemical class N1C(=O)\C(C)=C\C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C\[C@@H](C)[C@H](O)[C@H](OC)C[C@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-DVKIRIBLSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
GLWHPRRGGYLLRV-XLPZGREQSA-N [[(2S,3S,5R)-3-azido-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](N=[N+]=[N-])C1 GLWHPRRGGYLLRV-XLPZGREQSA-N 0.000 description 2
229940030360 abacavir / Lamivudine Drugs 0.000 description 2
229940114030 abacavir / Lamivudine / Zidovudine Drugs 0.000 description 2
229960003697 abatacept Drugs 0.000 description 2
229960002964 adalimumab Drugs 0.000 description 2
229930013930 alkaloids Natural products 0.000 description 2
229960003459 allopurinol Drugs 0.000 description 2
229960003550 alosetron Drugs 0.000 description 2
229960002932 anastrozole Drugs 0.000 description 2
230000002280 anti-androgenic Effects 0.000 description 2
230000002429 anti-coagulation Effects 0.000 description 2
230000001142 anti-diarrhea Effects 0.000 description 2
230000002921 anti-spasmodic Effects 0.000 description 2
239000000051 antiandrogen Substances 0.000 description 2
239000003146 anticoagulant agent Substances 0.000 description 2
239000003793 antidiarrheal agent Substances 0.000 description 2
108091007172 antigens Chemical group 0.000 description 2
102000038129 antigens Human genes 0.000 description 2
239000002246 antineoplastic agent Substances 0.000 description 2
239000002814 antineoplastic antimetabolite Substances 0.000 description 2
239000007900 aqueous suspension Substances 0.000 description 2
239000003613 bile acid Substances 0.000 description 2
230000035514 bioavailability Effects 0.000 description 2
229920002988 biodegradable polymer Polymers 0.000 description 2
239000004621 biodegradable polymer Substances 0.000 description 2
YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Chemical group N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
229960002685 biotin Drugs 0.000 description 2
235000020958 biotin Nutrition 0.000 description 2
239000011616 biotin Substances 0.000 description 2
229960000503 bisacodyl Drugs 0.000 description 2
150000004663 bisphosphonates Chemical class 0.000 description 2
239000008280 blood Substances 0.000 description 2
MPBVHIBUJCELCL-UHFFFAOYSA-N bondronat Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 2
239000006172 buffering agent Substances 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
150000007942 carboxylates Chemical class 0.000 description 2
239000008112 carboxymethyl-cellulose Substances 0.000 description 2
239000004359 castor oil Substances 0.000 description 2
230000003197 catalytic Effects 0.000 description 2
OKKJLVBELUTLKV-MZCSYVLQSA-N cd3od Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
101710014509 celF Proteins 0.000 description 2
230000024245 cell differentiation Effects 0.000 description 2
230000036755 cellular response Effects 0.000 description 2
229960003115 certolizumab pegol Drugs 0.000 description 2
201000006934 chronic myeloid leukemia Diseases 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
229940110456 cocoa butter Drugs 0.000 description 2
235000019868 cocoa butter Nutrition 0.000 description 2
229960001338 colchicine Drugs 0.000 description 2
201000006233 congestive heart failure Diseases 0.000 description 2
230000001276 controlling effect Effects 0.000 description 2
239000008120 corn starch Substances 0.000 description 2
229940099112 cornstarch Drugs 0.000 description 2
229960004544 cortisone Drugs 0.000 description 2
239000006071 cream Substances 0.000 description 2
125000004122 cyclic group Chemical group 0.000 description 2
VKIRRGRTJUUZHS-UHFFFAOYSA-N cyclohexane-1,4-diamine Chemical compound NC1CCC(N)CC1 VKIRRGRTJUUZHS-UHFFFAOYSA-N 0.000 description 2
PMATZTZNYRCHOR-UHFFFAOYSA-N cyclosporine A Chemical compound CCC1NC(=O)C(C(O)C(C)CC=CC)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(C(C)C)NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-UHFFFAOYSA-N 0.000 description 2
229950006418 dactolisib Drugs 0.000 description 2
229960002448 dasatinib Drugs 0.000 description 2
230000004059 degradation Effects 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
231100000080 dermatitis contact Toxicity 0.000 description 2
125000004431 deuterium atoms Chemical group 0.000 description 2
229960001259 diclofenac Drugs 0.000 description 2
DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 2
235000005911 diet Nutrition 0.000 description 2
230000037213 diet Effects 0.000 description 2
229960004192 diphenoxylate Drugs 0.000 description 2
238000007598 dipping method Methods 0.000 description 2
229940042399 direct acting antivirals Protease inhibitors Drugs 0.000 description 2
VXIHRIQNJCRFQX-UHFFFAOYSA-K disodium aurothiomalate Chemical compound [Na+].[Na+].[O-]C(=O)CC(S[Au])C([O-])=O VXIHRIQNJCRFQX-UHFFFAOYSA-K 0.000 description 2
238000006073 displacement reaction Methods 0.000 description 2
229960003668 docetaxel Drugs 0.000 description 2
229940043264 dodecyl sulfate Drugs 0.000 description 2
239000008298 dragée Substances 0.000 description 2
239000000428 dust Substances 0.000 description 2
239000000975 dye Substances 0.000 description 2
239000002158 endotoxin Substances 0.000 description 2
239000003623 enhancer Substances 0.000 description 2
239000002702 enteric coating Substances 0.000 description 2
230000002327 eosinophilic Effects 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
239000000262 estrogen Substances 0.000 description 2
108010038795 estrogen receptors Proteins 0.000 description 2
229960000403 etanercept Drugs 0.000 description 2
230000005713 exacerbation Effects 0.000 description 2
230000029142 excretion Effects 0.000 description 2
229960000255 exemestane Drugs 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
229960000390 fludarabine Drugs 0.000 description 2
229960005304 fludarabine phosphate Drugs 0.000 description 2
238000002866 fluorescence resonance energy transfer Methods 0.000 description 2
239000007850 fluorescent dye Substances 0.000 description 2
125000001153 fluoro group Chemical group F* 0.000 description 2
238000005755 formation reaction Methods 0.000 description 2
229960004421 formestane Drugs 0.000 description 2
229960003142 fosamprenavir Drugs 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
229960002584 gefitinib Drugs 0.000 description 2
239000000499 gel Substances 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
229960005277 gemcitabine Drugs 0.000 description 2
238000007429 general method Methods 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
XHVAWZZCDCWGBK-UHFFFAOYSA-M gold(1+);3,4,5-trihydroxy-6-(hydroxymethyl)oxane-2-thiolate Chemical compound [Au+].OCC1OC([S-])C(O)C(O)C1O XHVAWZZCDCWGBK-UHFFFAOYSA-M 0.000 description 2
IRPYFWIZKIOHQN-XTZHGVARSA-N gold;[(2R,3R,4S,5R,6S)-3,4,5-triacetyloxy-6-sulfanyloxan-2-yl]methyl acetate;triethylphosphane Chemical compound [Au].CC[PH+](CC)CC.CC(=O)OC[C@H]1O[C@@H]([S-])[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H]1OC(C)=O IRPYFWIZKIOHQN-XTZHGVARSA-N 0.000 description 2
229960001743 golimumab Drugs 0.000 description 2
108010086781 golimumab Proteins 0.000 description 2
XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 2
229960001442 gonadorelin Drugs 0.000 description 2
230000036541 health Effects 0.000 description 2
239000003481 heat shock protein 90 inhibitor Substances 0.000 description 2
108010037536 heparanase Proteins 0.000 description 2
125000004475 heteroaralkyl group Chemical group 0.000 description 2
229940121372 histone deacetylase inhibitors Drugs 0.000 description 2
229960003160 hyaluronic acid Drugs 0.000 description 2
229960005236 ibandronic acid Drugs 0.000 description 2
IFSDAJWBUCMOAH-HNNXBMFYSA-N idelalisib Chemical compound C1([C@@H](NC=2C=3N=CNC=3N=CN=2)CC)=NC2=CC=CC(F)=C2C(=O)N1C1=CC=CC=C1 IFSDAJWBUCMOAH-HNNXBMFYSA-N 0.000 description 2
239000000367 immunologic factor Substances 0.000 description 2
239000003018 immunosuppressive agent Substances 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
238000000099 in vitro assay Methods 0.000 description 2
230000028709 inflammatory response Effects 0.000 description 2
229960000598 infliximab Drugs 0.000 description 2
239000007972 injectable composition Substances 0.000 description 2
239000002850 integrase inhibitor Substances 0.000 description 2
229960004768 irinotecan Drugs 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
239000004816 latex Substances 0.000 description 2
239000008141 laxative Substances 0.000 description 2
230000002475 laxative Effects 0.000 description 2
229960003881 letrozole Drugs 0.000 description 2
238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
239000008297 liquid dosage form Substances 0.000 description 2
WMFOQBRAJBCJND-UHFFFAOYSA-M lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
229940120922 lopinavir and ritonavir Drugs 0.000 description 2
239000006210 lotion Substances 0.000 description 2
KHPKQFYUPIUARC-UHFFFAOYSA-N lumiracoxib Chemical compound OC(=O)CC1=CC(C)=CC=C1NC1=C(F)C=CC=C1Cl KHPKQFYUPIUARC-UHFFFAOYSA-N 0.000 description 2
239000000347 magnesium hydroxide Substances 0.000 description 2
235000012254 magnesium hydroxide Nutrition 0.000 description 2
OFOBLEOULBTSOW-UHFFFAOYSA-N malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 2
201000007924 marginal zone B-cell lymphoma Diseases 0.000 description 2
239000003771 matrix metalloproteinase inhibitor Substances 0.000 description 2
229940121386 matrix metalloproteinase inhibitors Drugs 0.000 description 2
MFMSWHJIFIRYNO-UHFFFAOYSA-N methyl 5,6-dihydro-4H-cyclopenta[b]thiophene-2-carboxylate Chemical compound C1CCC2=C1C=C(C(=O)OC)S2 MFMSWHJIFIRYNO-UHFFFAOYSA-N 0.000 description 2
239000004530 micro-emulsion Substances 0.000 description 2
150000007522 mineralic acids Chemical class 0.000 description 2
238000002156 mixing Methods 0.000 description 2
LTEMOXGFFHXNNS-UHFFFAOYSA-L monosodium aurothiomalate Chemical compound [Na+].OC(=O)CC(S[Au])C([O-])=O LTEMOXGFFHXNNS-UHFFFAOYSA-L 0.000 description 2
YNAVUWVOSKDBBP-UHFFFAOYSA-N morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
229940113083 morpholine Drugs 0.000 description 2
239000007922 nasal spray Substances 0.000 description 2
230000000926 neurological Effects 0.000 description 2
NHNBFGGVMKEFGY-UHFFFAOYSA-N nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
150000002829 nitrogen Chemical group 0.000 description 2
231100000344 non-irritating Toxicity 0.000 description 2
239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 description 2
239000004006 olive oil Substances 0.000 description 2
231100000590 oncogenic Toxicity 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
235000005985 organic acids Nutrition 0.000 description 2
230000002018 overexpression Effects 0.000 description 2
229960001756 oxaliplatin Drugs 0.000 description 2
229960003978 pamidronic acid Drugs 0.000 description 2
230000003071 parasitic Effects 0.000 description 2
239000002245 particle Substances 0.000 description 2
230000001717 pathogenic Effects 0.000 description 2
244000052769 pathogens Species 0.000 description 2
239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
239000000816 peptidomimetic Substances 0.000 description 2
230000002093 peripheral Effects 0.000 description 2
239000002831 pharmacologic agent Substances 0.000 description 2
239000012071 phase Substances 0.000 description 2
125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
OAICVXFJPJFONN-UHFFFAOYSA-N phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
239000011574 phosphorus Substances 0.000 description 2
238000002428 photodynamic therapy Methods 0.000 description 2
LHNIIDJUOCFXAP-UHFFFAOYSA-N pictrelisib Chemical compound C1CN(S(=O)(=O)C)CCN1CC1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 LHNIIDJUOCFXAP-UHFFFAOYSA-N 0.000 description 2
239000002574 poison Substances 0.000 description 2
201000006292 polyarteritis nodosa Diseases 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Inorganic materials [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
229960003081 probenecid Drugs 0.000 description 2
239000002599 prostaglandin synthase inhibitor Substances 0.000 description 2
230000001681 protective Effects 0.000 description 2
239000003528 protein farnesyltransferase inhibitor Substances 0.000 description 2
230000002685 pulmonary Effects 0.000 description 2
238000000746 purification Methods 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
BKXVVCILCIUCLG-UHFFFAOYSA-N raloxifene hydrochloride Chemical compound [H+].[Cl-].C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 BKXVVCILCIUCLG-UHFFFAOYSA-N 0.000 description 2
229960000759 risedronic acid Drugs 0.000 description 2
229960003452 romidepsin Drugs 0.000 description 2
239000000523 sample Substances 0.000 description 2
201000000980 schizophrenia Diseases 0.000 description 2
230000036303 septic shock Effects 0.000 description 2
230000035939 shock Effects 0.000 description 2
XUIMIQQOPSSXEZ-UHFFFAOYSA-N silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
229910052710 silicon Inorganic materials 0.000 description 2
239000010703 silicon Substances 0.000 description 2
201000010001 silicosis Diseases 0.000 description 2
150000003384 small molecules Chemical class 0.000 description 2
229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
MAKUBRYLFHZREJ-JWBQXVCJSA-M sodium;(2S,3S,4R,5R,6R)-3-[(2S,3R,5S,6R)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylate Chemical compound [Na+].CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@H](O)[C@H]1O MAKUBRYLFHZREJ-JWBQXVCJSA-M 0.000 description 2
YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 2
239000007921 spray Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000000758 substrate Substances 0.000 description 2
229940086735 succinate Drugs 0.000 description 2
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
239000003765 sweetening agent Substances 0.000 description 2
DKGAVHZHDRPRBM-UHFFFAOYSA-N t-BuOH Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
108010038329 tanezumab Proteins 0.000 description 2
229930003347 taxol Natural products 0.000 description 2
239000003277 telomerase inhibitor Substances 0.000 description 2
229960004964 temozolomide Drugs 0.000 description 2
229960001355 tenofovir disoproxil Drugs 0.000 description 2
VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 description 2
LLIIQRRYFRWRMS-UHFFFAOYSA-N tert-butyl N-(5,6-dihydro-4H-cyclopenta[b]thiophen-2-yl)carbamate Chemical compound C1CCC2=C1C=C(NC(=O)OC(C)(C)C)S2 LLIIQRRYFRWRMS-UHFFFAOYSA-N 0.000 description 2
125000003718 tetrahydrofuranyl group Chemical group 0.000 description 2
125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 2
YTPLMLYBLZKORZ-UHFFFAOYSA-N thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
229960005324 tiludronic acid Drugs 0.000 description 2
WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
108010078548 tocilizumab Proteins 0.000 description 2
229960003989 tocilizumab Drugs 0.000 description 2
229960001350 tofacitinib Drugs 0.000 description 2
UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 description 2
229960000303 topotecan Drugs 0.000 description 2
LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 description 2
229960000575 trastuzumab Drugs 0.000 description 2
230000001960 triggered Effects 0.000 description 2
229910052722 tritium Inorganic materials 0.000 description 2
YZCKVEUIGOORGS-NJFSPNSNSA-N tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 2
230000009959 type I hypersensitivity Effects 0.000 description 2
230000002792 vascular Effects 0.000 description 2
KDQAABAKXDWYSZ-JKDPCDLQSA-N vincaleukoblastine sulfate Chemical compound OS(O)(=O)=O.C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 KDQAABAKXDWYSZ-JKDPCDLQSA-N 0.000 description 2
229960004276 zoledronic acid Drugs 0.000 description 2
GZIFEOYASATJEH-VHFRWLAGSA-N δ-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-VHFRWLAGSA-N 0.000 description 2
UAGYHIZGHDGMCY-FNCVBFRFSA-N (2R,3S,4R,5R)-2-(hydroxymethyl)-5-pyrimidin-1-ium-1-yloxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1[N+]1=CC=CN=C1 UAGYHIZGHDGMCY-FNCVBFRFSA-N 0.000 description 1
FSIRXIHZBIXHKT-MHTVFEQDSA-N (2S)-2-[[4-[1-(2,4-diaminopteridin-6-yl)butan-2-yl]benzoyl]amino]pentanedioic acid Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CC(CC)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FSIRXIHZBIXHKT-MHTVFEQDSA-N 0.000 description 1
YKPYIPVDTNNYCN-INIZCTEOSA-N (3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide Chemical compound ONC(=O)[C@H]1C(C)(C)SCCN1S(=O)(=O)C(C=C1)=CC=C1OC1=CC=NC=C1 YKPYIPVDTNNYCN-INIZCTEOSA-N 0.000 description 1
DEQANNDTNATYII-OULOTJBUSA-N (4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 1
NBRQRXRBIHVLGI-OWXODZSWSA-N (4aS,5aR,12aR)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide Chemical compound C1C2=CC=CC(O)=C2C(O)=C(C2=O)[C@@H]1C[C@@H]1[C@@]2(O)C(O)=C(C(=O)N)C(=O)C1 NBRQRXRBIHVLGI-OWXODZSWSA-N 0.000 description 1
GWCNJMUSWLTSCW-SFQUDFHCSA-N (E)-2-cyano-3-(3,4-dihydroxyphenyl)-N-(4-phenylbutyl)prop-2-enamide Chemical compound C1=C(O)C(O)=CC=C1\C=C(/C#N)C(=O)NCCCCC1=CC=CC=C1 GWCNJMUSWLTSCW-SFQUDFHCSA-N 0.000 description 1
CTSHLCWTPAQAAB-PPHVVYHHSA-N (E)-3-amino-2-[(Z)-(3-hydroxy-4-oxocyclohexa-2,5-dien-1-ylidene)methyl]-3-sulfanylprop-2-enenitrile Chemical compound N\C(S)=C(/C#N)\C=C1\C=CC(=O)C(O)=C1 CTSHLCWTPAQAAB-PPHVVYHHSA-N 0.000 description 1
TUCIOBMMDDOEMM-RIYZIHGNSA-N (E)-N-benzyl-2-cyano-3-(3,4-dihydroxyphenyl)prop-2-enamide Chemical compound C1=C(O)C(O)=CC=C1\C=C(/C#N)C(=O)NCC1=CC=CC=C1 TUCIOBMMDDOEMM-RIYZIHGNSA-N 0.000 description 1
229920000160 (ribonucleotides)n+m Polymers 0.000 description 1
229940058015 1,3-butylene glycol Drugs 0.000 description 1
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
ZESRJSPZRDMNHY-YFWFAHHUSA-N 11-Deoxycorticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 ZESRJSPZRDMNHY-YFWFAHHUSA-N 0.000 description 1
DBPWSSGDRRHUNT-CEGNMAFCSA-N 17α-hydroxyprogesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 DBPWSSGDRRHUNT-CEGNMAFCSA-N 0.000 description 1
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
RTGDFNSFWBGLEC-SYZQJQIISA-N 2-(morpholin-4-yl)ethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enoate Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 1
PXBFMLJZNCDSMP-UHFFFAOYSA-N 2-Aminobenzamide Chemical class NC(=O)C1=CC=CC=C1N PXBFMLJZNCDSMP-UHFFFAOYSA-N 0.000 description 1
VHVPQPYKVGDNFY-TUJWMRSMSA-N 2-[(2S)-butan-2-yl]-4-[4-[4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-TUJWMRSMSA-N 0.000 description 1
GCSJOZFHZGHGTJ-UHFFFAOYSA-N 2-[2-[3,4-bis(2-hydroxyethoxy)oxolan-2-yl]-2-(2-hydroxyethoxy)ethoxy]ethyl formate Chemical compound O=COCCOCC(OCCO)C1OCC(OCCO)C1OCCO GCSJOZFHZGHGTJ-UHFFFAOYSA-N 0.000 description 1
TXGKRVFSSHPBAJ-JKSUJKDBSA-N 2-[[(1R,2S)-2-aminocyclohexyl]amino]-4-[3-(triazol-2-yl)anilino]pyrimidine-5-carboxamide Chemical compound N[C@H]1CCCC[C@H]1NC1=NC=C(C(N)=O)C(NC=2C=C(C=CC=2)N2N=CC=N2)=N1 TXGKRVFSSHPBAJ-JKSUJKDBSA-N 0.000 description 1
ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 1
AAOSLLBWWRKJIR-UHFFFAOYSA-N 2-chloro-1-pyrrolidin-1-ylethanone Chemical compound ClCC(=O)N1CCCC1 AAOSLLBWWRKJIR-UHFFFAOYSA-N 0.000 description 1
125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
WXPNDRBBWZMPQG-UHFFFAOYSA-N 2-methyl-4-(4-methylpiperazin-1-yl)-5H-thieno[3,2-c][1,5]benzodiazepine Chemical compound C1CN(C)CCN1C1=C(C=C(C)S2)C2=NC2=CC=CC=C2N1 WXPNDRBBWZMPQG-UHFFFAOYSA-N 0.000 description 1
229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
YQEMORVAKMFKLG-UHFFFAOYSA-N 2-stearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
108010024199 2C4 antibody Proteins 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
MJKVTPMWOKAVMS-UHFFFAOYSA-N 3 Hydroxycoumarin Chemical compound C1=CC=C2OC(=O)C(O)=CC2=C1 MJKVTPMWOKAVMS-UHFFFAOYSA-N 0.000 description 1
UZFPOOOQHWICKY-UHFFFAOYSA-N 3-[13-[1-[1-[8,12-bis(2-carboxyethyl)-17-(1-hydroxyethyl)-3,7,13,18-tetramethyl-21,24-dihydroporphyrin-2-yl]ethoxy]ethyl]-18-(2-carboxyethyl)-8-(1-hydroxyethyl)-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-2-yl]propanoic acid Chemical compound N1C(C=C2C(=C(CCC(O)=O)C(C=C3C(=C(C)C(C=C4N5)=N3)CCC(O)=O)=N2)C)=C(C)C(C(C)O)=C1C=C5C(C)=C4C(C)OC(C)C1=C(N2)C=C(N3)C(C)=C(C(O)C)C3=CC(C(C)=C3CCC(O)=O)=NC3=CC(C(CCC(O)=O)=C3C)=NC3=CC2=C1C UZFPOOOQHWICKY-UHFFFAOYSA-N 0.000 description 1
ZRPLANDPDWYOMZ-UHFFFAOYSA-M 3-cyclopentylpropanoate Chemical compound [O-]C(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-M 0.000 description 1
WTDRDQBEARUVNC-LURJTMIESA-N 3-hydroxy-L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
UXXQOJXBIDBUAC-UHFFFAOYSA-N 4-[6-methoxy-7-(3-piperidin-1-ylpropoxy)quinazolin-4-yl]-N-(4-propan-2-yloxyphenyl)piperazine-1-carboxamide Chemical compound COC1=CC2=C(N3CCN(CC3)C(=O)NC=3C=CC(OC(C)C)=CC=3)N=CN=C2C=C1OCCCN1CCCCC1 UXXQOJXBIDBUAC-UHFFFAOYSA-N 0.000 description 1
125000002471 4H-quinolizinyl group Chemical group C=1(C=CCN2C=CC=CC12)* 0.000 description 1
JOPSSWGWLCLPPF-RUDMXATFSA-N 5-[2-(2-carboxyethyl)-3-[(E)-6-(4-methoxyphenyl)hex-5-enoxy]phenoxy]pentanoic acid Chemical compound C1=CC(OC)=CC=C1\C=C\CCCCOC1=CC=CC(OCCCCC(O)=O)=C1CCC(O)=O JOPSSWGWLCLPPF-RUDMXATFSA-N 0.000 description 1
YJISHJVIRFPGGN-UHFFFAOYSA-N 5-[5-[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxy-6-[[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxymethyl]-3,4-dihydroxyoxan-2-yl]oxy-6-(hydroxymethyl)-2-methyloxane-3,4-diol Chemical compound O1C(CO)C(OC)C(O)C(O)C1OCC1C(OC2C(C(O)C(OC)C(CO)O2)O)C(O)C(O)C(OC2C(OC(C)C(O)C2O)CO)O1 YJISHJVIRFPGGN-UHFFFAOYSA-N 0.000 description 1
PDOQBOJDRPLBQU-QMMMGPOBSA-N 5-chloro-2-N-[(1S)-1-(5-fluoropyrimidin-2-yl)ethyl]-4-N-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine Chemical compound N([C@@H](C)C=1N=CC(F)=CN=1)C(N=1)=NC=C(Cl)C=1NC=1C=C(C)NN=1 PDOQBOJDRPLBQU-QMMMGPOBSA-N 0.000 description 1
QULDDKSCVCJTPV-UHFFFAOYSA-N 6-chloro-9-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]purin-2-amine Chemical compound COC1=C(C)C=NC(CN2C3=NC(N)=NC(Cl)=C3N=C2)=C1C QULDDKSCVCJTPV-UHFFFAOYSA-N 0.000 description 1
ILYBMUDLGFMEMU-UHFFFAOYSA-N 7-$l^{1}-oxidanyl-2,3,4,5,6,7-hexaoxoheptan-1-olate Chemical compound [O]C(=O)C(=O)C(=O)C(=O)C(=O)C(=O)C[O-] ILYBMUDLGFMEMU-UHFFFAOYSA-N 0.000 description 1
PBCZSGKMGDDXIJ-HQCWYSJUSA-N 7-Hydroxystaurosporine Chemical compound N([C@H](O)C1=C2C3=CC=CC=C3N3C2=C24)C(=O)C1=C2C1=CC=CC=C1N4[C@H]1C[C@@H](NC)[C@@H](OC)[C@]3(C)O1 PBCZSGKMGDDXIJ-HQCWYSJUSA-N 0.000 description 1
JJTNLWSCFYERCK-UHFFFAOYSA-N 7H-pyrrolo[2,3-d]pyrimidine Chemical class N1=CN=C2NC=CC2=C1 JJTNLWSCFYERCK-UHFFFAOYSA-N 0.000 description 1
IHOXNOQMRZISPV-YFKXAPIDSA-N 8-hydroxy-5-[(1R)-1-hydroxy-2-[1-(4-methoxyphenyl)propan-2-ylamino]ethyl]-1H-quinolin-2-one Chemical compound C1=CC(OC)=CC=C1CC(C)NC[C@H](O)C1=CC=C(O)C2=C1C=CC(=O)N2 IHOXNOQMRZISPV-YFKXAPIDSA-N 0.000 description 1
239000005541 ACE inhibitor Substances 0.000 description 1
101700040666 ACKR2 Proteins 0.000 description 1
PNEYBMLMFCGWSK-UHFFFAOYSA-N AI2O3 Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
GYDJEQRTZSCIOI-UHFFFAOYSA-N AMCHA Chemical compound NCC1CCC(C(O)=O)CC1 GYDJEQRTZSCIOI-UHFFFAOYSA-N 0.000 description 1
229940030495 ANTIANDROGEN SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM Drugs 0.000 description 1
229940116904 ANTIINFLAMMATORY THERAPEUTIC RADIOPHARMACEUTICALS Drugs 0.000 description 1
229950004810 ATAMESTANE Drugs 0.000 description 1
102100011565 AXL Human genes 0.000 description 1
206010000496 Acne Diseases 0.000 description 1
208000002874 Acne Vulgaris Diseases 0.000 description 1
208000002552 Acute Disseminated Encephalomyelitis Diseases 0.000 description 1
229940009456 Adriamycin Drugs 0.000 description 1
208000008190 Agammaglobulinemia Diseases 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
239000012103 Alexa Fluor 488 Substances 0.000 description 1
239000012109 Alexa Fluor 568 Substances 0.000 description 1
239000012110 Alexa Fluor 594 Substances 0.000 description 1
239000012112 Alexa Fluor 633 Substances 0.000 description 1
239000012115 Alexa Fluor 660 Substances 0.000 description 1
239000012116 Alexa Fluor 680 Substances 0.000 description 1
239000012099 Alexa Fluor family Substances 0.000 description 1
XJKJWTWGDGIQRH-BFIDDRIFSA-N Alginic acid Chemical compound O1[C@@H](C(O)=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](C)[C@@H](O)[C@H]1O XJKJWTWGDGIQRH-BFIDDRIFSA-N 0.000 description 1
206010001767 Alopecia universalis Diseases 0.000 description 1
239000005995 Aluminium silicate Substances 0.000 description 1
PZZYQPZGQPZBDN-UHFFFAOYSA-N Aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 description 1
229940063655 Aluminum stearate Drugs 0.000 description 1
DKNWSYNQZKUICI-UHFFFAOYSA-N Amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
229960003805 Amantadine Drugs 0.000 description 1
108010005474 Anaplastic Lymphoma Kinase Proteins 0.000 description 1
AEMFNILZOJDQLW-QAGGRKNESA-N Androstenedione Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 AEMFNILZOJDQLW-QAGGRKNESA-N 0.000 description 1
229960005471 Androstenedione Drugs 0.000 description 1
229960001232 Anecortave Drugs 0.000 description 1
YUWPMEXLKGOSBF-GACAOOTBSA-N Anecortave Chemical compound O=C1CC[C@]2(C)C3=CC[C@]4(C)[C@](C(=O)COC(=O)C)(O)CC[C@H]4[C@@H]3CCC2=C1 YUWPMEXLKGOSBF-GACAOOTBSA-N 0.000 description 1
208000009094 Anemia, Hemolytic, Autoimmune Diseases 0.000 description 1
206010002412 Angiocentric lymphomas Diseases 0.000 description 1
108090000644 Angiozyme Proteins 0.000 description 1
206010002556 Ankylosing spondylitis Diseases 0.000 description 1
229940046836 Anti-estrogens Drugs 0.000 description 1
229940064005 Antibiotic throat preparations Drugs 0.000 description 1
229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 1
229940042052 Antibiotics for systemic use Drugs 0.000 description 1
208000003343 Antiphospholipid Syndrome Diseases 0.000 description 1
108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
229940042786 Antitubercular Antibiotics Drugs 0.000 description 1
235000003276 Apios tuberosa Nutrition 0.000 description 1
206010059512 Apoptosis Diseases 0.000 description 1
229920002395 Aptamer Polymers 0.000 description 1
240000005781 Arachis hypogaea Species 0.000 description 1
235000010777 Arachis hypogaea Nutrition 0.000 description 1
235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
229940039856 Aricept Drugs 0.000 description 1
GVTLDPJNRVMCAL-UHFFFAOYSA-N Arofylline Chemical compound C1=2N=CNC=2C(=O)N(CCC)C(=O)N1C1=CC=C(Cl)C=C1 GVTLDPJNRVMCAL-UHFFFAOYSA-N 0.000 description 1
229950009746 Arofylline Drugs 0.000 description 1
229940046844 Aromatase inhibitors Drugs 0.000 description 1
229940072224 Asacol Drugs 0.000 description 1
229940072107 Ascorbate Drugs 0.000 description 1
229940009098 Aspartate Drugs 0.000 description 1
229960004754 Astemizole Drugs 0.000 description 1
GXDALQBWZGODGZ-UHFFFAOYSA-N Astemizole Chemical compound C1=CC(OC)=CC=C1CCN1CCC(NC=2N(C3=CC=CC=C3N=2)CC=2C=CC(F)=CC=2)CC1 GXDALQBWZGODGZ-UHFFFAOYSA-N 0.000 description 1
PEPMWUSGRKINHX-TXTPUJOMSA-N Atamestane Chemical compound C1C[C@@H]2[C@@]3(C)C(C)=CC(=O)C=C3CC[C@H]2[C@@H]2CCC(=O)[C@]21C PEPMWUSGRKINHX-TXTPUJOMSA-N 0.000 description 1
206010003827 Autoimmune hepatitis Diseases 0.000 description 1
206010003840 Autonomic nervous system imbalance Diseases 0.000 description 1
229940003504 Avonex Drugs 0.000 description 1
229960002756 Azacitidine Drugs 0.000 description 1
MBUVEWMHONZEQD-UHFFFAOYSA-N Azeptin Chemical compound C1CN(C)CCCC1N1C(=O)C2=CC=CC=C2C(CC=2C=CC(Cl)=CC=2)=N1 MBUVEWMHONZEQD-UHFFFAOYSA-N 0.000 description 1
208000003950 B-Cell Lymphoma Diseases 0.000 description 1
210000003719 B-Lymphocytes Anatomy 0.000 description 1
MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
BJDJEJIINKBPHY-UHFFFAOYSA-N BODIPY FL Chemical compound C1=C2C=CC(CCC(O)=O)=[N+]2[B-](F)(F)N2C(C)=CC(C)=C21 BJDJEJIINKBPHY-UHFFFAOYSA-N 0.000 description 1
RFLLOBSXBJAGST-UHFFFAOYSA-N BODIPY R6G Chemical compound C1=CC(CCC(=O)O)=[N+]([B-](N23)(F)F)C1=CC2=CC=C3C1=CC=CC=C1 RFLLOBSXBJAGST-UHFFFAOYSA-N 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
201000007815 Bannayan-Riley-Ruvalcaba syndrome Diseases 0.000 description 1
XUZMWHLSFXCVMG-UHFFFAOYSA-N Baricitinib Chemical compound C1N(S(=O)(=O)CC)CC1(CC#N)N1N=CC(C=2C=3C=CNC=3N=CN=2)=C1 XUZMWHLSFXCVMG-UHFFFAOYSA-N 0.000 description 1
229950000971 Baricitinib Drugs 0.000 description 1
MJJALKDDGIKVBE-UHFFFAOYSA-N Bastin Chemical compound C1=CC(C(C)(C)C)=CC=C1C(=O)CCCN1CCC(OC(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 MJJALKDDGIKVBE-UHFFFAOYSA-N 0.000 description 1
XFILPEOLDIKJHX-QYZOEREBSA-N Batimastat Chemical compound C([C@@H](C(=O)NC)NC(=O)[C@H](CC(C)C)[C@H](CSC=1SC=CC=1)C(=O)NO)C1=CC=CC=C1 XFILPEOLDIKJHX-QYZOEREBSA-N 0.000 description 1
229950001858 Batimastat Drugs 0.000 description 1
229940050390 Benzoate Drugs 0.000 description 1
241000349774 Bikinia letestui Species 0.000 description 1
210000001124 Body Fluids Anatomy 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
229960002802 Bromocriptine Drugs 0.000 description 1
OZVBMTJYIDMWIL-AYFBDAFISA-N Bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 1
MJQUEDHRCUIRLF-TVIXENOKSA-N Bryostatin 1 Chemical compound C([C@@H]1CC(/[C@@H]([C@@](C(C)(C)/C=C/2)(O)O1)OC(=O)/C=C/C=C/CCC)=C\C(=O)OC)[C@H]([C@@H](C)O)OC(=O)C[C@H](O)C[C@@H](O1)C[C@H](OC(C)=O)C(C)(C)[C@]1(O)C[C@@H]1C\C(=C\C(=O)OC)C[C@H]\2O1 MJQUEDHRCUIRLF-TVIXENOKSA-N 0.000 description 1
USUNCAQFNNEGBQ-MGCOHNPYSA-N C1C[C@@H](N)CC[C@@H]1N1CCOCC1 Chemical compound C1C[C@@H](N)CC[C@@H]1N1CCOCC1 USUNCAQFNNEGBQ-MGCOHNPYSA-N 0.000 description 1
AIFIVCWONKRRJQ-MGCOHNPYSA-N C1C[C@@H](O)CC[C@@H]1N1CCOCC1 Chemical compound C1C[C@@H](O)CC[C@@H]1N1CCOCC1 AIFIVCWONKRRJQ-MGCOHNPYSA-N 0.000 description 1
229940030609 CALCIUM CHANNEL BLOCKERS Drugs 0.000 description 1
229960004205 CARBIDOPA Drugs 0.000 description 1
101700083927 CCR1 Proteins 0.000 description 1
102100005860 CCR1 Human genes 0.000 description 1
101700024466 CCR10 Proteins 0.000 description 1
102100000148 CCR10 Human genes 0.000 description 1
101700067628 CCR2 Proteins 0.000 description 1
102100005862 CCR2 Human genes 0.000 description 1
101700070842 CCR3 Proteins 0.000 description 1
102100005861 CCR3 Human genes 0.000 description 1
101700024589 CCR4 Proteins 0.000 description 1
102100003247 CCR4 Human genes 0.000 description 1
101700019063 CCR6 Proteins 0.000 description 1
102100008133 CCR6 Human genes 0.000 description 1
102100008151 CCR7 Human genes 0.000 description 1
101700029727 CCR8 Proteins 0.000 description 1
102100008148 CCR8 Human genes 0.000 description 1
101700076302 CCR9 Proteins 0.000 description 1
102100008149 CCR9 Human genes 0.000 description 1
102100019449 CD79B Human genes 0.000 description 1
101700045471 CD79B Proteins 0.000 description 1
101700083324 CDC25 Proteins 0.000 description 1
101710012460 CDC25C Proteins 0.000 description 1
VYXSBFYARXAAKO-BXMGYBSLSA-N CHEMBL3183331 Chemical compound Cl.C1=2C=C(C)C(NCC)=CC=2OC2=C\C(=N\CC)C(C)=CC2=C1C1=CC=CC=C1C(=O)OCC VYXSBFYARXAAKO-BXMGYBSLSA-N 0.000 description 1
CFBUZOUXXHZCFB-OYOVHJISSA-N CHEMBL511115 Chemical compound COC1=CC=C([C@@]2(CC[C@H](CC2)C(O)=O)C#N)C=C1OC1CCCC1 CFBUZOUXXHZCFB-OYOVHJISSA-N 0.000 description 1
ANRHNWWPFJCPAZ-UHFFFAOYSA-M CHEMBL593252 Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 1
STNVXNYQNKDYBT-ZKCHVHJHSA-N CN(C)[C@H]1CC[C@H](O)CC1 Chemical compound CN(C)[C@H]1CC[C@H](O)CC1 STNVXNYQNKDYBT-ZKCHVHJHSA-N 0.000 description 1
AHJLTFQZZBPRNB-QAQDUYKDSA-N CN(CC(N1CCCC1)=O)[C@H](CC1)CC[C@@H]1Nc1ccnc2c1c(CCC1)c1[s]2 Chemical compound CN(CC(N1CCCC1)=O)[C@H](CC1)CC[C@@H]1Nc1ccnc2c1c(CCC1)c1[s]2 AHJLTFQZZBPRNB-QAQDUYKDSA-N 0.000 description 1
101700011366 CXCR1 Proteins 0.000 description 1
102100014035 CXCR1 Human genes 0.000 description 1
102100014012 CXCR2 Human genes 0.000 description 1
101700079756 CXCR3 Proteins 0.000 description 1
102100002226 CXCR3 Human genes 0.000 description 1
102100002212 CXCR4 Human genes 0.000 description 1
101710003734 CXCR4 Proteins 0.000 description 1
101710025651 CXCR5 Proteins 0.000 description 1
102100002072 CXCR5 Human genes 0.000 description 1
102100014446 CYBB Human genes 0.000 description 1
102100004057 CYP3A4 Human genes 0.000 description 1
101710007540 CYP3A4 Proteins 0.000 description 1
ZVHNDZWQTBEVRY-UHFFFAOYSA-N CYT387 Chemical compound C1=CC(C(NCC#N)=O)=CC=C1C1=CC=NC(NC=2C=CC(=CC=2)N2CCOCC2)=N1 ZVHNDZWQTBEVRY-UHFFFAOYSA-N 0.000 description 1
229960005069 Calcium Drugs 0.000 description 1
229960003563 Calcium Carbonate Drugs 0.000 description 1
CJZGTCYPCWQAJB-UHFFFAOYSA-L Calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
DSSYKIVIOFKYAU-UHFFFAOYSA-N Camphor Chemical compound C1CC2(C)C(=O)CC1C2(C)C DSSYKIVIOFKYAU-UHFFFAOYSA-N 0.000 description 1
TZFNLOMSOLWIDK-JTQLQIEISA-N Carbidopa Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 description 1
206010007541 Cardiac disease Diseases 0.000 description 1
BLMPQMFVWMYDKT-NZTKNTHTSA-N Carfilzomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)[C@]1(C)OC1)NC(=O)CN1CCOCC1)CC1=CC=CC=C1 BLMPQMFVWMYDKT-NZTKNTHTSA-N 0.000 description 1
108010022830 Cetuximab Proteins 0.000 description 1
ZPEIMTDSQAKGNT-UHFFFAOYSA-N Chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
229960001076 Chlorpromazine Drugs 0.000 description 1
LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 description 1
229950001653 Cilomilast Drugs 0.000 description 1
MYSWGUAQZAJSOK-UHFFFAOYSA-N Ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 1
PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
229960002689 Clemastine Fumarate Drugs 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
229940038717 Copaxone Drugs 0.000 description 1
OMFXVFTZEKFJBZ-HJTSIMOOSA-N Corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 1
WHBHBVVOGNECLV-OBQKJFGGSA-N Cortodoxone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 WHBHBVVOGNECLV-OBQKJFGGSA-N 0.000 description 1
201000002847 Cowden syndrome Diseases 0.000 description 1
206010051906 Cowden's disease Diseases 0.000 description 1
102000003903 Cyclin-Dependent Kinases Human genes 0.000 description 1
108090000266 Cyclin-Dependent Kinases Proteins 0.000 description 1
QASFUMOKHFSJGL-LAFRSMQTSA-N Cyclopamine Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H](CC2=C3C)[C@@H]1[C@@H]2CC[C@@]13O[C@@H]2C[C@H](C)CN[C@H]2[C@H]1C QASFUMOKHFSJGL-LAFRSMQTSA-N 0.000 description 1
BGTOWKSIORTVQH-UHFFFAOYSA-N Cyclopentanone Chemical compound O=C1CCCC1 BGTOWKSIORTVQH-UHFFFAOYSA-N 0.000 description 1
208000003311 Cytochrome P-450 Enzyme Inhibitors Diseases 0.000 description 1
UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytosar Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 1
RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
229940030606 DIURETICS Drugs 0.000 description 1
CKLJMWTZIZZHCS-UHFFFAOYSA-N DL-aspartic acid Chemical compound OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
XAUDJQYHKZQPEU-KVQBGUIXSA-N Decitabine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 1
NEFBYIFKOOEVPA-UHFFFAOYSA-K Dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
235000019739 Dicalciumphosphate Nutrition 0.000 description 1
229960000525 Diphenhydramine Hydrochloride Drugs 0.000 description 1
USIUVYZYUHIAEV-UHFFFAOYSA-N Diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 1
ZPWVASYFFYYZEW-UHFFFAOYSA-L Dipotassium phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
229960002563 Disulfiram Drugs 0.000 description 1
AUZONCFQVSMFAP-UHFFFAOYSA-N Disulfiram Chemical compound CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 description 1
ADEBPBSSDYVVLD-UHFFFAOYSA-N Donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 1
108020004461 Double-Stranded RNA Proteins 0.000 description 1
102000027776 ERBB3 Human genes 0.000 description 1
101700041204 ERBB3 Proteins 0.000 description 1
102000027777 ERBB4 Human genes 0.000 description 1
101700023619 ERBB4 Proteins 0.000 description 1
102100016041 EZH2 Human genes 0.000 description 1
101700041849 EZH2 Proteins 0.000 description 1
229940047652 Ear Drops Drugs 0.000 description 1
210000004696 Endometrium Anatomy 0.000 description 1
210000001163 Endosomes Anatomy 0.000 description 1
229940095399 Enema Drugs 0.000 description 1
241000792859 Enema Species 0.000 description 1
JRURYQJSLYLRLN-BJMVGYQFSA-N Entacapone Chemical compound CCN(CC)C(=O)C(\C#N)=C\C1=CC(O)=C(O)C([N+]([O-])=O)=C1 JRURYQJSLYLRLN-BJMVGYQFSA-N 0.000 description 1
229940116977 Epidermal Growth Factor Drugs 0.000 description 1
WHWZLSFABNNENI-UHFFFAOYSA-N Epinastine Chemical compound C1C2=CC=CC=C2C2CN=C(N)N2C2=CC=CC=C21 WHWZLSFABNNENI-UHFFFAOYSA-N 0.000 description 1
229940082789 Erbitux Drugs 0.000 description 1
229960005309 Estradiol Drugs 0.000 description 1
229940011871 Estrogens Drugs 0.000 description 1
MNJVRJDLRVPLFE-UHFFFAOYSA-N Etoricoxib Chemical compound C1=NC(C)=CC=C1C1=NC=C(Cl)C=C1C1=CC=C(S(C)(=O)=O)C=C1 MNJVRJDLRVPLFE-UHFFFAOYSA-N 0.000 description 1
HKVAMNSJSFKALM-WDSGEKFTSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)\C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-WDSGEKFTSA-N 0.000 description 1
229940012356 Eye Drops Drugs 0.000 description 1
102100004573 FLT3 Human genes 0.000 description 1
102100013182 FLT4 Human genes 0.000 description 1
101710030894 FLT4 Proteins 0.000 description 1
206010016256 Fatigue Diseases 0.000 description 1
210000003608 Feces Anatomy 0.000 description 1
LSLYOANBFKQKPT-UHFFFAOYSA-N Fenoterol Chemical compound C=1C(O)=CC(O)=CC=1C(O)CNC(C)CC1=CC=C(O)C=C1 LSLYOANBFKQKPT-UHFFFAOYSA-N 0.000 description 1
RWTNPBWLLIMQHL-UHFFFAOYSA-N Fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 1
229960000354 Fexofenadine hydrochloride Drugs 0.000 description 1
239000004606 Fillers/Extenders Substances 0.000 description 1
KKGQTZUTZRNORY-UHFFFAOYSA-N Fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 description 1
229940063190 Flagyl Drugs 0.000 description 1
WMWTYOKRWGGJOA-CENSZEJFSA-N Fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 1
229950005309 Fostamatinib Drugs 0.000 description 1
GKDRMWXFWHEQQT-UHFFFAOYSA-N Fostamatinib Chemical compound COC1=C(OC)C(OC)=CC(NC=2N=C(NC=3N=C4N(COP(O)(O)=O)C(=O)C(C)(C)OC4=CC=3)C(F)=CN=2)=C1 GKDRMWXFWHEQQT-UHFFFAOYSA-N 0.000 description 1
108010082772 GFB 111 Proteins 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
241000206672 Gelidium Species 0.000 description 1
229950009073 Gimatecan Drugs 0.000 description 1
UIVFUQKYVFCEKJ-OPTOVBNMSA-N Gimatecan Chemical compound C1=CC=C2C(\C=N\OC(C)(C)C)=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UIVFUQKYVFCEKJ-OPTOVBNMSA-N 0.000 description 1
208000007565 Gingivitis Diseases 0.000 description 1
229940084910 Gliadel Drugs 0.000 description 1
102000003676 Glucocorticoid Receptors Human genes 0.000 description 1
108090000079 Glucocorticoid Receptors Proteins 0.000 description 1
AWUCVROLDVIAJX-UHFFFAOYSA-N Glycerol 3-phosphate Chemical compound OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
229960002449 Glycine Drugs 0.000 description 1
229940015042 Glycopyrrolate Drugs 0.000 description 1
VPNYRYCIDCJBOM-UHFFFAOYSA-M Glycopyrronium bromide Chemical compound [Br-].C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 VPNYRYCIDCJBOM-UHFFFAOYSA-M 0.000 description 1
229960003690 Goserelin Acetate Drugs 0.000 description 1
206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
229940093922 Gynecological Antibiotics Drugs 0.000 description 1
208000005721 HIV Infections Diseases 0.000 description 1
LNEPOXFFQSENCJ-UHFFFAOYSA-N Haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 1
102000003693 Hedgehog Proteins Human genes 0.000 description 1
108090000031 Hedgehog Proteins Proteins 0.000 description 1
229920002971 Heparan sulfate Polymers 0.000 description 1
LIIALPBMIOVAHH-UHFFFAOYSA-N Herniarin Chemical compound C1=CC(=O)OC2=CC(OC)=CC=C21 LIIALPBMIOVAHH-UHFFFAOYSA-N 0.000 description 1
239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
238000006736 Huisgen cycloaddition reaction Methods 0.000 description 1
102000008100 Human Serum Albumin Human genes 0.000 description 1
108091006822 Human Serum Albumin Proteins 0.000 description 1
208000004454 Hyperalgesia Diseases 0.000 description 1
208000007999 Hyperesthesia Diseases 0.000 description 1
206010020983 Hypogammaglobulinaemia Diseases 0.000 description 1
206010021067 Hypopituitarism Diseases 0.000 description 1
FUCOMWZKWIEKRK-UHFFFAOYSA-N IC1CCCCC1 Chemical compound IC1CCCCC1 FUCOMWZKWIEKRK-UHFFFAOYSA-N 0.000 description 1
229960003444 IMMUNOSUPPRESSANTS Drugs 0.000 description 1
229940071829 Ilaris Drugs 0.000 description 1
229960003685 Imatinib mesylate Drugs 0.000 description 1
206010021425 Immune system disease Diseases 0.000 description 1
108010034143 Inflammasomes Proteins 0.000 description 1
102000003996 Interferon beta Human genes 0.000 description 1
108090000467 Interferon beta Proteins 0.000 description 1
102000004889 Interleukin-6 Human genes 0.000 description 1
108090001005 Interleukin-6 Proteins 0.000 description 1
229940096397 Interleukin-8 Drugs 0.000 description 1
XKTZWUACRZHVAN-VADRZIEHSA-N Interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 1
108010018951 Interleukin-8B Receptors Proteins 0.000 description 1
102000015696 Interleukins Human genes 0.000 description 1
108010063738 Interleukins Proteins 0.000 description 1
210000004020 Intracellular Membrane Anatomy 0.000 description 1
108090000862 Ion Channels Proteins 0.000 description 1
102000004310 Ion Channels Human genes 0.000 description 1
229940084651 Iressa Drugs 0.000 description 1
SRJOCJYGOFTFLH-UHFFFAOYSA-N Isonipecotic acid Chemical compound OC(=O)C1CCNCC1 SRJOCJYGOFTFLH-UHFFFAOYSA-N 0.000 description 1
PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 1
229960003648 Ixazomib Drugs 0.000 description 1
102000036507 JAK family Human genes 0.000 description 1
108091020259 JAK family Proteins 0.000 description 1
102100019517 JAK1 Human genes 0.000 description 1
101700034277 JAK1 Proteins 0.000 description 1
101700016050 JAK2 Proteins 0.000 description 1
102100019516 JAK2 Human genes 0.000 description 1
102100019518 JAK3 Human genes 0.000 description 1
101700007593 JAK3 Proteins 0.000 description 1
210000001503 Joints Anatomy 0.000 description 1
102100013180 KDR Human genes 0.000 description 1
101710009391 KIT Proteins 0.000 description 1
101710033922 KRAS Proteins 0.000 description 1
102000010638 Kinesin Human genes 0.000 description 1
108010063296 Kinesin Proteins 0.000 description 1
TYQCGQRIZGCHNB-JLAZNSOCSA-N L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
239000002067 L01XE06 - Dasatinib Substances 0.000 description 1
239000005536 L01XE08 - Nilotinib Substances 0.000 description 1
239000002144 L01XE18 - Ruxolitinib Substances 0.000 description 1
239000002177 L01XE27 - Ibrutinib Substances 0.000 description 1
229940001447 Lactate Drugs 0.000 description 1
JYTUSYBCFIZPBE-AMTLMPIISA-N Lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
229940067606 Lecithin Drugs 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
VNYSSYRCGWBHLG-AMOLWHMGSA-N Leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 description 1
YEESKJGWJFYOOK-IJHYULJSSA-N Leukotriene D4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@H](N)C(=O)NCC(O)=O YEESKJGWJFYOOK-IJHYULJSSA-N 0.000 description 1
229960003088 Loratadine Drugs 0.000 description 1
JCCNYMKQOSZNPW-UHFFFAOYSA-N Loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 1
229950008745 Losoxantrone Drugs 0.000 description 1
YROQEQPFUCPDCP-UHFFFAOYSA-N Losoxantrone Chemical compound OCCNCCN1N=C2C3=CC=CC(O)=C3C(=O)C3=C2C1=CC=C3NCCNCCO YROQEQPFUCPDCP-UHFFFAOYSA-N 0.000 description 1
208000008551 Lyme Neuroborreliosis Diseases 0.000 description 1
206010025169 Lyme disease Diseases 0.000 description 1
210000004698 Lymphocytes Anatomy 0.000 description 1
102000008072 Lymphokines Human genes 0.000 description 1
108010074338 Lymphokines Proteins 0.000 description 1
208000006557 Lymphoma, B-Cell, Marginal Zone Diseases 0.000 description 1
208000006116 Lymphomatoid Granulomatosis Diseases 0.000 description 1
101700067074 MAPK Proteins 0.000 description 1
101710041325 MAPKAPK2 Proteins 0.000 description 1
101700036258 MECOM Proteins 0.000 description 1
101710039852 METAP1 Proteins 0.000 description 1
101710012506 METAP2 Proteins 0.000 description 1
208000009865 MYD88 Deficiency Diseases 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
206010026798 Mantle cell lymphomas Diseases 0.000 description 1
OCSMOTCMPXTDND-OUAUKWLOSA-N Marimastat Chemical compound CNC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO OCSMOTCMPXTDND-OUAUKWLOSA-N 0.000 description 1
229950008959 Marimastat Drugs 0.000 description 1
210000000138 Mast Cells Anatomy 0.000 description 1
208000000516 Mast-Cell Leukemia Diseases 0.000 description 1
208000006971 Mastocytoma Diseases 0.000 description 1
SGDBTWWWUNNDEQ-LBPRGKRZSA-N Melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
206010027476 Metastasis Diseases 0.000 description 1
ZVNPWFOVUDMGRP-UHFFFAOYSA-N Metol Chemical compound OS(O)(=O)=O.CNC1=CC=C(O)C=C1.CNC1=CC=C(O)C=C1 ZVNPWFOVUDMGRP-UHFFFAOYSA-N 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
229940042472 Mineral Oil Drugs 0.000 description 1
PVLJETXTTWAYEW-UHFFFAOYSA-N Mizolastine Chemical compound N=1C=CC(=O)NC=1N(C)C(CC1)CCN1C1=NC2=CC=CC=C2N1CC1=CC=C(F)C=C1 PVLJETXTTWAYEW-UHFFFAOYSA-N 0.000 description 1
229950008814 Momelotinib Drugs 0.000 description 1
WOFMFGQZHJDGCX-ZULDAHANSA-N Mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 description 1
208000008770 Multiple Hamartoma Syndrome Diseases 0.000 description 1
SWZXEVABPLUDIO-WSZYKNRRSA-N N-[(2S)-3-methoxy-1-[[(2S)-3-methoxy-1-[[(2S)-1-[(2R)-2-methyloxiran-2-yl]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]-2-methyl-1,3-thiazole-5-carboxamide Chemical compound N([C@@H](COC)C(=O)N[C@@H](COC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)[C@]1(C)OC1)C(=O)C1=CN=C(C)S1 SWZXEVABPLUDIO-WSZYKNRRSA-N 0.000 description 1
KXBDTLQSDKGAEB-UHFFFAOYSA-N N-[3-[[5-fluoro-2-[4-(2-methoxyethoxy)anilino]pyrimidin-4-yl]amino]phenyl]prop-2-enamide Chemical compound C1=CC(OCCOC)=CC=C1NC1=NC=C(F)C(NC=2C=C(NC(=O)C=C)C=CC=2)=N1 KXBDTLQSDKGAEB-UHFFFAOYSA-N 0.000 description 1
VZZJRYRQSPEMTK-CALCHBBNSA-N N-[6-[(2S,6R)-2,6-dimethylmorpholin-4-yl]pyridin-3-yl]-2-methyl-3-[4-(trifluoromethoxy)phenyl]benzamide Chemical compound C1[C@@H](C)O[C@@H](C)CN1C(N=C1)=CC=C1NC(=O)C1=CC=CC(C=2C=CC(OC(F)(F)F)=CC=2)=C1C VZZJRYRQSPEMTK-CALCHBBNSA-N 0.000 description 1
101700065330 NLRP3 Proteins 0.000 description 1
102100017336 NLRP3 Human genes 0.000 description 1
101710033916 NRAS Proteins 0.000 description 1
102100001119 NRAS Human genes 0.000 description 1
IXQIUDNVFVTQLJ-UHFFFAOYSA-N Naphthofluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C(C=CC=1C3=CC=C(O)C=1)=C3OC1=C2C=CC2=CC(O)=CC=C21